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The research project that I present with this Ph.D. thesis is the result of these years of 
work and study at the Biophysics Laboratory of the Physics department of the University 
of Genoa, and it has evolved under the supervision of my Professors Alberto Diaspro and 
Mauro Robello. 
This research concerned a receptor, GABAA receptor, which allows modulating the 
neuronal transmission in the Central Nervous System through its activation by the 
inhibitory neurotransmitter GABA. 
The methodological approaches can be multiple and can be faced from different points 
of view, as well as a faceted mirror reflects the different aspects of the same reality. 
In this case, a reality that affects the study and observation of events involving the 
infinitely small, such as neurons, and which cannot be seen with the naked eye. 
The neuronal transmission regulates our emotions, thoughts, relationships with the 
external world, and our life, integrating and transforming the information from electric 
signals of our neuronal circuit brain. 
These signals come from the passage of ions through channels in the cellular plasma 
membrane; an imbalance is enough to cause pathologies involving the Central Nervous 
System, i.e., epilepsy and other neuropsychiatric conditions.  
 Therefore, it is necessary to combine the use of techniques that allow identifying 
biological mechanisms based on neuronal conduction to understand and, in this way, to 
be able to modulate the function. 
This is how it was thought to couple two distinct physical techniques, 
electrophysiology, and optical microscopy, to precisely follow the GABAA receptor 
activation in a limited cell portion with the uncaging method. 
This method enables selecting a region of interest on the neuron for verifying 
differences in the GABAA receptor modulation after the activation by its neurotransmitter 
and pharmacological molecules. 
The purpose can be achieved thanks to the use of inert or inactive molecules until they 
are activated by light where and when needed: these are the caged compounds. The 




In the last decades, in the literature, several papers have been published works about 
caged compounds [1-10]; in this project, the uncaging of a caged molecule, RuBi-GABA, 
was exhaustively investigated and characterized. 
The first part of the thesis deals with the biological background: GABA and 
GABAergic transmission, cerebellum, and Antisecretory Factor. 
In the second chapter, caged compounds are considered; the attention is focused on 
caged neurotransmitters and, in particular, caged GABA. 
Biophysical approaches are then described, in which the physical methods of 
electrophysiology and optical microscopy are presented as techniques for the study of 
biological mechanisms and their function. 
In chapter 4, the instrumentation and the preparations used for carrying out the 
experiments are reported in materials and methods. 
The thesis ends with the results and their analysis. 
In the first part of the results, the uncaging method was studied as a useful technique 
for activating the receptor in localized areas of interest. 
Hence, various physical parameters that may influence GABAA receptor activation during 
the uncaging event have been considered, chosen, and studied in a spatially and 
temporally confined way [11]. 
After studying all the physiological variations due to changes in these parameters, it 
was decided to move on to the use of the Antisecretory Factor, a pharmacological 
molecule previously studied during my Master’s Thesis [12]. 
This factor was provided by Dr. Stefan Lange of the University of Gothenburg (Sweden), 
discoverer of this molecule, who also studied and investigated its function in various body 
areas [13-16]. 
The Antisecretory Factor has a facilitating action on the GABAA receptor in the presence 
of the neurotransmitter GABA. 
The second part of the results reports how this pharmacological molecule action 
mechanism might change on a limited number of receptors and in different parts of the 
neuron, such as soma, growth cones, and neurites. 
The study of the receptor responses in a confined cell area may open the door to future 
studies that can be used for the topical application of drugs on a specific target without 
activating the non-specific response of cells not of interest, thanks to the photoactivation 
of selective caged compounds. 
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Chapter 1: Biological background 
 
1.1 GABA and GABAergic receptors 
 
1.1.1 The neurotransmitter GABA 
 
γ-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the Central 
Nervous System of mammalians; it is at least in 30% of the synapsis [17]. It carries out 
its function binding receptors in the plasma membrane of pre and postsynaptic neurons. 
Eugene Roberts and Sam Frankel identified it for the first time in the ‘50, but its 
inhibitory function was discovered later. 
It is not uniformly distributed in the nervous system; substantia nigra, globus pallidus, 
hypothalamus, corpora quadrigemina, cerebral cortex, hippocampus, and cerebellum are 
the structures with the highest GABA concentration. 
GABA is synthesized in the neuronal cytoplasm from the amino acid glutamine: 
glutamine is converted into glutamate by a glutaminase. After a decarboxylation reaction, 
glutamate is transformed in GABA by the glutamate decarboxylase enzyme (GAD) 
thanks to the cofactor pyridoxal-phosphate [18-22]. 
The neo-synthesized GABA is stored in the axonal terminal in synaptic vesicles through 
vesicular transporters (VGAT) by electrical and pH gradient generated by a proton pump. 
A stimulus opens calcium channels; calcium enters into the cell, and, because of the 
increase of its concentration, GABA is released into the synaptic space after the vesicle 
fusion with the plasma membrane of the neuron. 
This neurotransmitter acts on receptors in the postsynaptic neuron membrane, inducing 
activation of inhibitory signals, but at the same time, it works on presynaptic receptors 
allowing a modulation in the release of the neurotransmitter. 
After GABA binding to the receptors and its physiological action, the presynaptic 
neurons, and glial cells (astrocytes) pick it up through membrane transporters (GAT). It 
may be directly accumulated in the synaptic vesicles, ready to be released after a new 
stimulation (presynaptic neuron); or it is catabolized by the enzyme GABA transaminase 
(GABA-T) and by the NAD-dependent succinic semialdehyde dehydrogenase. 
The transaminase deaminates GABA to succinic semialdehyde and transfers the amino 
group to a molecule of α-ketoglutarate to produce glutamate [23]. NAD-dependent 
succinic semialdehyde dehydrogenase oxidizes succinic semialdehyde forming succinic 





Figure 1.1: Metabolic pathway of GABA. 
 
A glutamine synthase converts glutamate into glutamine, which is released and captured 




Figure 1.2: Synthesis, release, and catabolism of GABA by a GABAergic synapse. Copyright 
(2014) Wiley. Used with permission from Yoon B. E. et al. Glial GABA, synthesized by 





GABA controls the neuronal excitability in the nervous system. In essence, the 
modulation of its activity, particularly positive and facilitating, at the receptor level is the 
mechanism of action of a large number of sedative, muscle relaxant, hypnotic, and anti-
epileptic drugs, benzodiazepines, and general anesthetics. 




1.1.2 GABA receptors 
 
GABA receptors are divided into three different types: GABAA, GABAB, and GABAC. 
The differences among them are based on the molecular structure, signal transduction 
mechanism, distribution, and pharmacological profile.  
GABAA receptor is a ligand-gated receptor of 5 subunits assembled to form a central 
anion-selective transmembrane pore that allows chloride passage. 
Chloride permeability involves membrane hyperpolarization (chloride enters into the 
cell), which decreases the probability that excitatory postsynaptic potentials can reach the 
threshold for generating the action potential. 
In different regions of the Central Nervous System (i.e., spinal cord, the dendrites of 
some hippocampal and cortical neurons) [26], a membrane depolarization can occur 
because of the activation of receptors that determines a loss of negative charges (Cl– 
moves out the cell). The resulting depolarization can generate an action potential for the 
activation of the voltage-dependent Na+ channels [24]. This phenomenon is due to a pre-
existing electrochemical gradient for Cl–, which results in a driving force for the exit from 
the cell of this anion. In turn, this is determined by the presence on the neuronal membrane 
of a Na+, Cl– transporter (to be precise: a Na+, K+, 2Cl– cotransporter) which accumulates 
chloride in the inside of the neuron utilizing the energy released by the simultaneous 
transport of Na+ along its electrochemical gradient [27]. Instead, when the increase of Cl- 
permeability results in hyperpolarization, this is due to the activity of a K+, Cl- 
cotransporter (KCC2) which sets the equilibrium potential for Cl- at the equilibrium 
potential for K+, which is hyperpolarized in respect of the resting membrane potential. 
In particular, the cells have a resting membrane potential (Vm) which results from an 
unequal distribution of ions on both sides of the plasma membrane. The factors affecting 
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the membrane potential are the ion concentration and the membrane's permeability to 
these ions. 
The equation that describes the membrane potential for a single ion is the Nernst 








     (1.1) 
 
Where R is the ideal gas constant, T the temperature, F the Faraday constant, z the 
charge of the ion, and [ion] is the concentration of the ion outside (out) and inside (int) 
the cell. 
The concentration of chloride in the extracellular fluid (≈ 108 mM) is higher than the 








≈ −63 𝑚𝑉      (1.2) 
 
Sodium, potassium, and chloride are the ions that influence the membrane potential; 
the contribution of each ion to the membrane potential is proportional to its ability to 















     (1.3) 
 
Where R is the ideal gas constant, T the temperature, F the Faraday constant, PK, PNa, 
and PCl the permeabilities of the membrane to the ions K
+, Na+ and Cl– respectively, and 
[K+], [Na+] and [Cl–] the concentrations of K+, Na+, and Cl– ions [28]. 
GABAA receptor has several binding sites for different molecules; for this reason, it is 
an essential target of drugs such as benzodiazepines and barbiturates to treat various 
neuropsychiatric conditions [29] and drugs for the induction and maintenance of general 
anesthesia [30, 31]. 
The second type of GABA receptor identified is the GABAB receptor; it is a 
metabotropic receptor associated with a G protein. It is made up of 7 transmembrane 
domains, an extracellular N-terminal portion, and an intracellular C-terminal portion. 
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These receptors are mainly distributed presynaptically and act as autoreceptors for 
GABAergic neurons or heteroreceptors on non-GABAergic terminals. Even if less 
abundantly, they are also found on the postsynaptic membrane, dendrites, and soma. 
They are activated by the endogenous ligand GABA and by the agonist baclofen; they 
do not respond to drugs active on GABAA receptors such as benzodiazepines and 
barbiturates and the competitive antagonist bicuculline [32]; their antagonists are saclofen 
[33] and phaclofen. 
The functional GABAB receptor consists of a heterodimer. The interaction of two 
subtypes composes it, GABABR1 and GABABR2, which interact with their C-terminal 
domains (coiled-coil structure) [34]. GABABR1 contains the binding site for GABA, 
agonists, and antagonists; GABABR2 interacts with a G protein and transfers the receptor 
complex on the plasma membrane. 
The activation of presynaptic GABAB receptors leads to a decrease in Ca
2+ voltage-
dependent channel conductance, a reduction in the flow of Ca2+ ions, and resulting 
inhibition of the release of neurotransmitters by exocytosis [33, 35]. In the postsynaptic 
neurons, these receptors induce a K+ channels conductance increase with a 
hyperpolarizing effect due to the increment in the efflux of K+ ions [24, 33, 36]. 
GABAC receptor is an ionotropic receptor, as GABAA receptors. It is a pentameric 
channel receptor, permeable to chloride, and it is mainly localized in the vertebrate retina. 
It can produce homomeric or heteromeric complexes. It is composed of ρ subunits (ρ1, ρ2, 
and ρ3) that are considered part of the GABAA receptor subunit family [37]. 
These receptors' physiological function is not yet clear, but they have a high sensitivity 
to GABA, produce small currents, and do not desensitize [37]. 
They are insensitive to the antagonists active on GABAA (bicuculline) and the agonist of 
GABAB receptor baclofen, do not respond to the administration of benzodiazepines, 










1.1.3 GABAA receptors 
 
Structure and subunits 
 
GABAA receptor is a ligand-gated receptor permeable to Cl
– ions, highly sensitive to 
the selective agonist muscimol, and the competitive antagonist bicuculline. 
It consists of 5 subunits assembled to form a central transmembrane pore; each subunit 
presents an extracellular N-terminal domain of about 200 amino acids, a small 
extracellular C-terminal portion, and four transmembrane hydrophobic regions called 
M1, M2, M3, and M4 (Figure 1.3). 
These receptors belong to the Cys-loop receptor superfamily with the nicotinic 
acetylcholine, the glycine, and the 5 -HT3 receptors. In the first portion of the N-terminal 
region of each subunit, there is a loop of 13 amino acids between two cysteines which 
form an SS-bond. The M2 segment forms the structure and the ionic selectivity of the 
channel; a long variable intracellular stretch (loop) is between M3 and M4 segments. In 





Figure 1.3: Schematic representation of the GABAA receptor. Transmembrane domains (M1-
M4), amino and carboxy-terminal are represented on the left; on the right is shown the 
arrangement of the transmembrane regions in the various subunits of the receptor for the 
formation of the central pore permeable to Cl–. Copyright (2002) Wiley. Used with permission 
from Watanabe M. et al. GABA and GABA receptors in the central nervous system and other 




Significant variability among GABAA receptors is known due to the presence of 16 
different receptor subunits encoded by 19 genes: 6 subunits α (α1 – 6), 3 β (β1 – 3), 3 γ (γ1 – 
3), δ, ε, θ and π [39]. The combination of different classes of subunits leads to the 
formation of GABAA receptors with various pharmacological properties.  
Each subunit of the same class has a homology of 60-80%, and the homology between 
subunits of different classes is 30% [40]. Functional GABAA receptors have two α 
subunits, two β subunits, and one of γ, δ or ε subunits. The most expressed receptors are 
composed of the combination α1-β2-γ2 in a ratio 2: 2: 1 [41]. 
GABA neurotransmitter binds GABAA receptor in a site that involves α and β subunits; 
each receptor consists of two α and two β subunits. Therefore two molecules of GABA 






Figure 1.4: Transverse view of the GABAA receptor. The subunits and binding sites for GABA 
and benzodiazepines are highlighted. Copyright (2016) Wiley. Used with permission from 
Gravielle M. C. Activation-induced regulation of GABAA receptors: Is there a link with the 











Immunohistochemistry and in situ hybridization studies have allowed verifying the 
distribution of the different subunits in several brain regions: 
- α1, β2, β3, and γ2 are widely diffused in different cell types in the brain and show the 
same pattern of diffusion [42]; 
- α2, α3, α5, and δ are limited to some cell populations [42];  
- α1 is in regions where α2 is not expressed or where it is not much expressed [43]; 
- α3 is localized where levels of α1 are low [42, 43]; 
- α4 is mainly distributed in the hippocampus and thalamus [42, 44, 45]; 
- α5 is prevalent in brain regions linked to memory and learning functions such as the 
hippocampus [42]; 
- α6 is expressed almost exclusively in cerebellar granule cells [46]; 
- ε is only found in some portions of the hypothalamus and hippocampus [47]. 
θ subunit is not well known; π subunit was detected in organs not belonging to the Central 
Nervous System such as uterus, prostate, lungs, and thymus [48], it can form GABAA 
receptor in association with α, β and/or γ subunits and it allows the bond with 
pregnanolone, an endogenous steroid. 
 
 
Binding sites, agonists, and antagonists 
 
Different binding sites for several compounds characterize the GABAA receptor 
because of the combinations of different subunits: the sites for GABA, benzodiazepines, 
barbiturates, picrotoxin, neurosteroids, general anesthetics, and ethanol are the most 
known and studied. 
 
GABA binding site 
It is between α and β subunits. It is well conserved among the different isoforms. The 
interaction with the endogenous molecule or with a GABA-mimetic (muscimol) allows, 
after a modification of the receptor complex, the opening of the Cl– permeable channel, 
and generally results in membrane hyperpolarization, and the generation of an inhibitory 






Benzodiazepine binding site 
It is in GABAA receptors composed of α, β, and γ subunits. 
This site is located between α and γ interfaces; the receptor sensitivity depends on isoform 
type. Receptors formed by the γ2 subunit show higher sensitivity to benzodiazepines than 
those with the γ1 subunit [49]. 
Benzodiazepines or non-benzodiazepine agonist interaction, in the presence of GABA, 
allows an increase in the receptor activation. The Cl– permeability improves the GABA 
action with a consequent rise in the ion channel opening frequency. The effects are 
anxiolytic, muscle relaxant, sedative, and hypnotic. In particular, if benzodiazepines 
interact with GABAA receptors with α1 subunits, the results are sedatives, anesthetics, and 
anticonvulsants, anxiolytic with α2 subunit, while with α3 or α5, the final effect is muscle 
relaxation. 
α1 subunit exhibits high sensitivity to benzodiazepines such as diazepam and 
quazepam and ligands as the imidazopyridine zolpidem. Zolpidem has an intermediate 
affinity for α2 and α3, and it binds α5 subunit with low affinity; receptors composed of α4 
and α6 subunits in combination with β and γ2 subunits do not bind traditional 
benzodiazepines and non-benzodiazepine agonists such as zolpidem but interact with 
high affinity with imidazobenzodiazepines, typically flumazenil [50]. 
Therefore, the efficacy and potency of the benzodiazepines depend on the α component 
[39]. 
This site is also recognized by a class of negative mediators, such as the inverse agonist 
β-carboline, which determines an opposite (inverse) action of benzodiazepines: it 
generates anxiogenic and convulsive effects. 
The evidence that benzodiazepines and inverse agonists bind the same site is 
demonstrated by the fact that the competitive antagonist flumazenil can block both the 
anxiolytic and anxiogenic effects. The capability to determine opposite effects depending 
on the interaction with inverse agonists or agonists is due to the GABA allosteric site 









Barbituric binding site 
It is between M2 and M3 transmembrane domain interfaces. When it is activated by 
barbiturates, the Cl– conductance increases, the channel opening time is extended, and the 
neuronal activity decreases, also when GABA is not present. 
Barbiturates, widely used in the past as hypnotics and sedatives, are dangerous, 
causing tolerance and dependence. For this reason, benzodiazepines have replaced these 
drugs. However, phenobarbital is still used as an anti-epileptic drug, especially in 
developing countries [51]. 
Active antagonists are unknown for this binding site. 
 
Picrotoxin and TBPS binding site (t-butylbicyclophosphorothionate) 
It is inside the Cl– channel; the bond to the non-competitive antagonist picrotoxin or 
the TBPS blocks the channel function and induces opposite effects than those mediated 
by GABA. 
 Picrotoxin interacts with the M2 transmembrane region of α and β subunits [37] and 
blocks the channel; this site is also known as the "convulsant site" because it causes 
anxiety and convulsions [50]. 
 
Neuroactive steroid-binding site 
Two binding sites for neuroactive steroids have been identified. The first is in the M1 
transmembrane region of the α subunit, and it facilitates the action of GABA by 
determining an allosteric modulation, and the second one is between α and β subunits. It 
involves modulation of the channel receptor similar to the action of barbiturates. 
The different isoforms of the subunits that form the receptor lead to various sensitivity 
towards different neuroactive steroids. For example, studies on recombinant receptors 
consisting of α1, α2 or α6 subunits in combination with β1 or β2 are more sensitive to the 
action of the neurosteroid allopregnanolone compared to subunits α3, α4, and α5. δ subunit 
is not directly involved in forming the binding site, but it plays an essential role in 
increasing these active molecules’ activity on the GABAA receptor. 
Receptors with the γ1 subunit are more sensitive to the interaction with neuroactive 






Ethanol and anesthetic binding site 
The binding site for ethanol and volatile anesthetics appears to be at the interface 
between M2 and M3 transmembrane domains. Two amino acids (S270 and A291 of α1 
subunit) in this receptor region are involved in allosteric modulation [52] 
It is not yet clear how ethanol acts on the GABAA receptor. Different studies have led 
to contradictory results [50]. 
Ethanol enhances the GABAA receptor function. Its effects, which can be overlapped 
with those of benzodiazepines and barbiturates, are increased by GABA agonists such as 
muscimol and reduced by antagonistic agents such as bicuculline. 
Anesthetics raise the inhibitory function of the receptor even in the absence of the 
endogenous neurotransmitter if they are administered intravenously and in high 
concentrations; this action, called GABA-mimetic, determines a direct effect on the 






Figure 1.5: Schematic representation of the structure of the GABAA receptor. Copyright (2002) 
Wiley. Used with permission from Korpi E. R.et al. Drug interactions at GABAA receptors. Prog 










1.2 The Cerebellum 
 
The cerebellum is an organ of the Central Nervous System mainly involved in the 
regulation of muscle tone, planning and coordination of movements, posture and balance 
[53]. 
It develops from the neural tube, which forms three primary vesicles in its anterior 
part: forebrain, midbrain, and hindbrain; the posterior part remains cylindrical and 
originates the spinal cord. 
The hindbrain gives rise to the myelencephalon, from which the medulla oblongata 
develops, and the metencephalon, that forms the cerebellum [54]. 
The cerebellum consists of a central part, called vermis, and two cerebellar 
hemispheres; it is located dorsally to the brainstem, with which it is connected through 
three peduncles, and below the occipital poles, from which it is separated by the tentorium 
cerebelli, a lamina of dura mater. 
The external surface shows a series of large transversal fissures, the deepest of which 
divides it into lobes; according to the phylogenetic origin, it is separated into three 
portions. The oldest part, the archicerebellum, and the paleocerebellum already appear in 
the “lower vertebrates”. The neocerebellum, which includes the cerebellar hemispheres, 
is only in the “higher vertebrates”. 
The cerebellum has a cortex of grey matter surrounding a medullary center of white 
matter; the cerebellar nuclei are localized in the medullary center, while the cortex is 
subdivided into three different zones: the granular layer, the ganglion or Purkinje cell 
layer, and the molecular layer. 
Two neuronal cell types form the granular layer, the cerebellar cortex innermost 
layer: the Granule and the Golgi cells. The Granule cells project their axons towards the 
molecular layer, where they divide into T and run parallel, forming Parallel fibers. 
The Golgi cells modulate the activity of Granule cells. 
The intermediate layer consists of Purkinje cells, neurons with a typical flask shape. The 
soma base originates an axon that reaches the medullary center after crossing the granular 
layer. They are the only cell type to leave the cerebellar cortex to interact with the nuclei 
of white matter: in fact, the axons of the other neurons are involved in the formation of 
intracortical circuits. 
From the cell body of Purkinje cells, a dendrite originates and, after reaching the 
molecular layer, branches off, creating a dendritic arborization that receives Parallel fibers 
through synaptic contacts. 
15 
 
The molecular layer is the outermost layer; it contains inhibitory interneurons (Basket 
and Stellate cells) that interact with Purkinje cells, the dendritic arborization of Purkinje 
cells, Parallel fibers formed by Granule axons, and Climbing fibers. 
The afferent fibers that reach the cerebellum are the Climbing and the Mossy fibers. 
The Climbing fibers, which originate from the inferior olivary nucleus, cross the first two 
cortical layers and in the molecular layer surround the Purkinje cell arborizations. The 
Mossy fibers, which derive from the pons and spinal cord neurons, project into the 





Figure 1.6: Subdivision of the cerebellar cortex and related neuronal types. Copyright © 2015 
Mosconi M. W., Wang Z., Schmitt L. M., Tsai P. and Sweeney J.A. The role of cerebellar circuitry 
alterations in the pathophysiology of autism spectrum disorders. Front Neurosci 9: 296. Frontiers 
Research Foundation. doi: 10.3389/fnins.2015.00296 [55]. 
 
Typical synaptic structures formed by the excitatory terminations of the Mossy fibers 
are the "glomeruli", where single large ends of Mossy fibers innervate more dendrites 
from different cerebellar Granule cells, which also receive GABAergic inhibitory 
innervation by Golgi cells [56]. 
The deep cerebellar nuclei of the cerebellum in the medullary center are four pairs. 
They are reached by the Purkinje cells' axons and collaterals of the Climbing and mossy 
fibers before entering the cortex and emit neurites going out from the cerebellum. 
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In the middle-lateral part, the deep cerebellar nuclei are distinguished in the globose and 
emboliform nuclei, which form the interposed nucleus, and the dentate nucleus, more 
developed and related to the neocerebellum. 
The axons are directed to the brain motor cortex through the cerebello-thalamo-cortical 
and the cerebello-rubro-thalamo-cortical pathway from the nuclei. The information is 
transmitted from the cerebellum to the telencephalon allowing gradual movements. 
The inputs that arrive at the cerebellum allow programming movements and motor 
learning; through the spinocerebellar tract, the proprioceptive information concerning the 
body's position comes from the periphery, and through the cortico-ponto-cerebellar fibers, 
the cerebellum receives the motor information elaborated by the cerebral cortex. 
All neurons in the cerebellar cortex synthesize the inhibitory GABA neurotransmitter 
except for Granule cells that release glutamate, an excitatory neurotransmitter. 
Only the axons of Purkinje cells leave the cortex and contact the cerebellar nuclei; we can 
consider these as the principal cells that modulate the nuclei function through an 
inhibitory stimulus. 
Also, the Climbing and Mossy fibers interact, in an excitatory way, with the cerebellar 
nuclei. 
Therefore, the cerebellum activity result derives from the integration of inhibitory signals 
coming from the cortex and excitatory on the deep cerebellar nuclei through the Mossy 
and Climbing fibers. 
Purkinje cells are excited by Climbing and Parallel fibers and inhibited by all other types 



















1.3 The Antisecretory Factor 
 
1.3.1 The discovery of a new molecule 
 
The Antisecretory Factor is an endogenous protein of 41 kDa expressed in different 
mammalian tissues and plasma [57]. This factor was identified in the 1980s, and it has an 
inhibitory function against hypersecretion induced by exposure to enterotoxins 
(especially to CT, cholera toxin) or due to chronic inflammatory diseases. 
This protein was purified for the first time from the intestinal mucosa and the pig 
pituitary gland [13] using methods such as isoelectric focusing, gel filtration, and agarose 
gel affinity chromatography [16]. 
The cDNA sequence was then cloned [57], and experiments were conducted to find the 
active site presents in the molecule [58]. Several peptides containing the sequence with 
antisecretory activity were synthesized to verify the possible pharmacological use in 
different conditions that induce intestinal hypersecretion and in situations of imbalance 
in the transport of liquids in other body compartments. 
Although the Antisecretory Factor (AF) mechanism of action is mostly unknown, it is 
hypothesized that the antisecretory activity occurs through the nervous pathway. 
However, it can not be ignored direct action on ion channels that are involved in the 
hypersecretion of Cl– ions and H2O: in fact, it regulates ion transport in Deiters cells, 
inhibiting the passage of chloride ions through the cell membrane [59]. Furthermore, the 
intestinal fluid hypersecretion causes a nervous stimulation which, conducted centrally 
by the vagus nerve, acts on the adenohypophysis inducing the release of the AF factor in 
the blood to reach the peripheral organs with the activation of a further 
secretion/activation of the AF itself. 
The distribution of the Antisecretory Factor was studied by immunohistochemistry and 
in situ hybridization of messenger RNA [15]; some cellular populations (i.e., different 
types of epithelia, leukocytes, endocrine cells, and neurons) have shown high expression, 
synthesis, and accumulation capacity of this protein [16]. 
Some foods, such as hydrothermally processed cereals (HPC), can increase AF blood 
levels by a mechanism of "false" intestinal hypersecretion due to a hypertonic signal in 
their passage into the small intestine. This capacity has clinical applications to improve 
the symptomatology of chronic inflammatory bowel diseases [60]. In Sweden, it has 
allowed preventing gastrointestinal diseases in pig and cattle breeding, avoiding the use 
of antibiotics [14]. The hydrothermal treatment of these cereals in a process similar to 
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malting produces many monomers/dimers of carbs and amino acids [16]. In particular, 
the carbs derive from the hydrolysis of the starch of the cereals themselves. With the 
substitution of single macromolecules with many smaller molecules, this process 
determines hypertonicity on the "wet" surface of the cereals in contact with the intestinal 
mucosa. This hypertonic signal causes an osmotic "suction" of liquid from the intestinal 
epithelium that "mimics" the abnormal release of fluid in diarrhea processes. This signal 




1.3.2 Structure and active sites 
 
Thanks to cloning, the AF sequence was obtained, and it was possible to study its 
structure. 
The genes encoding for AF are located on human chromosomes 1, 19, 23, and 
pseudogenes are present on chromosomes 10 and 15 [16]. 
The complete length of the human AF sequence is 1309 bp, in which a coding part of 
1131 bp can be distinguished [57]. In the mouse, 5 different variants were identified 
(Rpn10a – Rpn10e) with a 67 – 96% homology with the human protein. In particular, the 
first 250 amino acids are conserved, while the C – terminal sequence differs [16]. 
AF subjected to enzymatic digestion with trypsin has an antisecretory activity twice as 
high as the action of the whole protein; this increase in the inhibitory capacity led to the 
synthesis of peptide fragments of different lengths for the identification of the active 
antisecretory site [58]. 
Nine peptides from the recombinant protein and four smaller fragments were synthesized, 
a total of 13 peptides (see Table 1.1): five of them did not show antisecretory activity, 
and seven, containing amino acids 36 – 42, were particularly active. 
The data showed that the antisecretory site is in the region between the amino acids 35 
and 43, and it has the sequence (I)VCHSKTR. 
In the N-terminal region of the AF molecule, four cysteine groups form disulfide bridges 






Table 1.1: Peptide fragments synthesized from the recombinant AF protein; for each peptide is 
shown the nucleotide and amino acid length and the dose (moles injected into the rat), which 
determines the inhibition of 50% of the secretion induced by the cholera toxin. Copyright (1997) 
Wiley. Used with permission from Johansson E. et al. Identification of an active site in the 
antisecretory factor protein. Biochim Biophys Acta, Elsevier [58]. 
 
The AF peptide formed by 16 amino acids (AF-16), including the antisecretory site, is 
the most stable fragment during laboratory experiments, determines a protective and 
regulatory effect in several damaged tissues, normalizes intracranial pressure, and 






Figure 1.7: Molecular structure of the AF-16 peptide. Reprinted (adapted) with permission from 
Matson Dzebo M. et al. Enhanced cellular uptake of antisecretory peptide AF-16 through 




Also, the site in the N-terminal region is involved in the anti-inflammatory action. 
Studying the immunohistochemical distribution of AF, it has been hypothesized a 
possible role in the immune system. In lymphoid organs (i.e., spleen, lymph nodes, and 
thymus), AF is expressed abundantly in macrophages and cells with dendritic 
morphology; in the central nervous system, it is present in perivascular cells, necessary 
for the regulation of anti-inflammatory reactions, and in the intestine is widely localized 
in Peyer's plaques [63]. 
From protein structure prediction models based on the sequence information [64], it 
appears to be a von Willebrand domain between residues 5 and 188 of the N-terminal that 
would mediate protein-protein interactions [16]. 
The C-terminal portion of AF presents a site involved in ubiquitination and forms part of 
the 19S proteasome regulatory subunit [65]. 
Fascinating is that the AF factor interacts with the flotillin-1 protein in the nervous 
system [66, 67]. Flotillin-1 is a membrane protein and a component of the so-called lipid 
rafts that participate in transport processes of receptors at postsynaptic sites of the 






















In vivo experiments have shown that AF is a potent inhibitor of intestinal secretion 
induced by cholera toxin [13] and toxin A produced by Clostridium difficile [68]. The 
cholera toxin, and probably also the toxin A produced by Clostridium difficile, causes 
hypersecretion of chloride and water from the epithelial cells of the small intestine due to 
the prolonged opening of anionic channels due to their phosphorylation. The AF factor 
could reach its effect by acting on the nervous system interneurons and secretory 
complexes. 
The influence of the antisecretory factor in GABAergic transmission was considered: 
GABA represents the primary inhibitory neurotransmitter of the Central Nervous System 
of mammals and is present with its GABAA receptors in the Enteric Nervous System [29, 
69, 70]. However, such receptors in the Enteric Nervous System appear to have above all 
an excitatory function [29, 69, 70, 71], although the final result of their activation depends 
on whether they are in circuits that innervate motor or excitatory or inhibitory neurons. 
Ultimately, it does not appear possible in the Enteric Nervous System to apply the 
convenient conclusion that seems valid in the adult mammalian brain: increased activity 
of the GABAA receptors equal more significant inhibition and behaviourally anxiolytic, 
sedation, anti-epileptic action. 
Thus, the influences of the AF factor on the Enteric Nervous System and the secretory 
phenomena through effects on GABAA receptors should be evaluated in the context of 
intricate enteric nerve circuits. 
A more simplistic approach was to directly assess the effects of the AF factor on the 
large anionic channels potently activated in the intestine's epithelial cells from the cholera 
toxin. One model used was studying the chloride ion permeability properties of the 
plasma membranes of the large Deiters neurons of the mammalian brain trunk. This 
approach has suggested that AF can function directly as a blocker of such anionic 
channels, as a sort of "plug" [59]. 
Returning to the "GABAA centric receptor" approach, neuronal systems of the Central 
Nervous System were studied as models. In the CA1 region of the hippocampus, the effect 
of AF on pyramidal cells and their interneurons was studied; AF promotes an increase in 
the GABAergic inhibitory signal on the interneurons of the radiated layer, primarily by 
increasing the extrasynaptic tonic inhibition resulting in an AF mediated disinhibition of 
the pyramidal neurons [72]. 
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However, it remains clear that these last approaches and the one presented here are 
among these, have the purpose fundamentally to understand the "modules" of the 
functioning of the factor that can later be used and integrated within a better 
understanding of the mechanisms of the Enteric Nervous System. 
In recent years, the focus on AF function has also turned to clinical purposes. In the 
plasma of healthy people, it predominates the inactive form of AF; if exposed to agents 
that cause gastrointestinal disorders, AF is rapidly transformed into an active form to 
regularize and normalize the transport of water and ions in the gut [66]. 
Consumption of cereals hydrothermally treated with a process similar to malting by 
individuals suffering from inflammatory bowel disease increases plasma levels of AF 
and, at the same time, is accompanied by an improvement in physical well-being and 
quality of life with reduction of clinical symptoms [60]. 
Children with acute and chronic diarrhea may present a health improvement after 
consuming egg yolk rich in AF. This food with high doses of preformed antisecretory 
factor could be useful for prophylaxis in populations where gastrointestinal diseases are 
endemic [73, 74]. 
AF's possible role is the regulation of endolymph transport in the inner ear: vertigo 
symptoms in patients with Ménière's syndrome could be due to an imbalance in the 
production and/or transport of endolymph [75]. The treatment with AF would determine 
homeostasis control in the inner ear by regulating the secretion of endolymph. 
Furthermore, hydrothermally processed cereals (HPC) consumption has led to a reduction 
in vertigo because of the increase in AF production in treated patients [75-77]. 
A more recent randomized double-blind study with placebo controls led to discordant 
results compared to previous work. In essence, 53% of patients (17 patients out of 32) 
treated with HPC showed a functional improvement, but this did not result statistically 
significant compared to 44% (14 patients out of 32) found in placebo patients [78]; this 
would require an investigative approach aimed at analyzing and deepening this aspect of 
the antisecretory factor for the understanding of its mechanism of action and its role. 
However, the work of Ingvardsen and Klokker [78] is not immune to criticism, having 
been conducted on no-hospitalized patients and therefore not adequately evaluated from 
"compliance" in treatment (in this case, a particularly decisive aspect). Moreover, in this 





Chapter 2: Caged compounds 
 
In cell biology, an important issue is how particular molecules or ions influence cell 
functions. This question can be investigated by introducing probes of interest in live cells 
and observing the effects. A conventional method is microinjection of the molecules into 
cells or using a probe that can be photo-activated and precisely controlled in space and 
time [79]. 
These probes, called “caged compounds”, are chemically modified, and their 
biological activity is masked until UV-visible light activate them when and where the 
exposure occurs. This approach is suitable because illumination can be easily controlled 
in timing, location, and amplitude. 
The term caged is based on the concept that biologically active species could get trapped 
inside a large molecule that would be open or dismembered after illumination [1]. 
These optical probes are similar to pro-peptides whose activity is suppressed by the 
presence of sequences covalently linked to the molecule, inhibiting their function. 
Chemical thermal reactions release the functional peptides from the precursors such as 
photolysis breaks the covalent bond in caged compounds, enabling the active form [8]. 
The caged group must fulfill some principles to be useful for physiology: 
- It should cause the biomolecule to become inert at the working concentration; 
adding the caging chromophore to a functionally crucial side of the biomolecule 
usually renders it inactive towards its target [1, 80]. 
- It should instantly release the biomolecule in high yield; it is essential how 
excitation translates to release of the caged molecule, a property measured as the 
quantum yield (QY; Φ, unitless). Furthermore, most ionotropic neurotransmitter 
receptors activate on a fast time scale; the photolytic release must occur faster 
than the signaling to be activated for mimicking endogenous receptor signaling 
[1, 80]. 
- It should have an efficient light absorption, measured as the extinction 
coefficient (ε, unit: M-1 cm-1) [80]. 
- It should have hydrolytic stability at physiological pH during the experiments 
[80]. 
- It should be soluble at the experimental concentration [80]. 
- It should not interact or interfere with other molecules [1]. 




Several caged compounds are available, i.e., amino acids, neurotransmitters, enzymes, 
and peptides; different caged probes allow studying intracellular ion levels, typically 
calcium and sodium, which regulate and transduce cytoplasmatic signals. 
Also, caged fluorophores are attached in biomolecules for measuring the system steady-
state or dynamics conditions after the photolysis reaction [1, 79]. 
Nowadays, different caged frameworks have been described and are commercially 
accessible; the widely used are the nitroaromatic groups as CNB, DMNB, MNI [81, 82], 
CDNI [8], that are activated by light in 300-410 nm range [1, 8, 83, 84] or DEAC450 [6], 
and RuBi [2, 85] with an uncaging absorption spectrum into the blue range (440-500 nm) 
[8]. 
The spatially precision of the uncaging is realized by focusing the light. The localized 
illumination can reveal the spatial diffusion of caged compounds and provide a reduction 
in their use. 
Conventional lighting through microscope objectives is related to a double cone, as in 
confocal microscopy; although the highest photon density is in the focus plane, the planes 
above and below the focus collect photons. 
For favoring the photolysis as firmly as possible to the focus plane, it is required the 
absorption of more than one photon; in particular, the two-photon regime is the most 
diffused [1]. 
In this way, two red-infrared photons are simultaneously absorbed by a molecule and 
emitted as a single photon with a half wavelength [86]; this phenomenon necessitates 
tight focusing of a pulsed laser of 10-13 s width repeating every 10-8 s. 
Also, infrared wavelengths provide less scattering and damage but more penetration than 
UV in tissues. 
Besides one- and two-photon uncaging, other significant parameters are reported in 
the literature, as well as laser power [6, 87-89], exposure time [90], and plane distance 
from the cell target [2, 6, 8, 88, 91]. 
Uncaging has many useful features and advantages compared to other methods. The 
intracellular compartment is accessible to the photorelease, cells are transparent to 
uncaging light, and the inert compound can be loaded [83]. 
It is fast (from sub-microseconds to milliseconds), so channel-gating kinetics can be 
calculated. It is possible to repeat and control the release of the caged compound, 
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calibrating the uncaging efficiency as a function of incident light intensity or via 
intracellular imaging techniques [83]. 
Finally, caged compounds provide a much less invasive means of producing 
concentration jumps than rapid flow techniques, causing physical perturbation of the 
sample [83]. 
Other characteristics of caged compounds are related to purity and stability. Caged 
compounds should be extremely pure; impurities could cause a response before the 
illumination of the caged compound [83]. 
Moreover, they must be hydrolytically and enzymatically stable for the duration of the 
experiment; chemical instability of certain caged neurotransmitters could liberate enough 
of the caged species to produce desensitization before illumination [83]. 
 
 
2.1 Caged neurotransmitters 
 
The uncaging method has proved useful in some physiological studies. A process is 
measured while a light flash is applied to manipulate a physiologically relevant or 
pharmacologically active photosensitive molecule. In particular, it is the case of the 
investigation of receptor activations in the nervous system [92]. 
These probe compounds are prepared via covalent appendage of a light-sensitive 
protecting group (the “cage”) to a signaling molecule that is unable to activate its target 
until the light brokes the bond [93]. 
Once uncaged, the neurotransmitter becomes active, and it can interact with its receptor 
site, inducing a physiological variation that can be measured with a suitable experimental 
apparatus. 
Caged neurotransmitter compounds are composed of aromatic rings to produce 
photosensitivity. The simplest type of caging chromophores is quite water-soluble; no 
organic solvents should be present in the buffer, even small amounts of it can be toxic 
and jeopardize the experiment success [94]. 
The first caged neurotransmitters described were a series of photoactivatable 
acetylcholine, active on nicotinic acetylcholine receptors (AChR) and studied coupling 
the uncaging with the electrophysiological techniques [1]. 
The most known was Bis-Q, a reversible agonist in its trans form, but with not negligible 
side effects as desensitization and inactivation of the receptors [95]; for this reason, 
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carbamoylcholine replaced it [96]. This new probe was the beginning of the development 
of most caged neurotransmitters, such as glycine [97], glutamate [98], serotonin [99], 
dopamine [4], and GABA [2, 8, 87, 100, 101]. 
The functional distribution and connectivity of neurons are studied by optical 
stimulation of postsynaptic receptors using caged neurotransmitters in neuronal culture 
and ex vivo (i.e., brain slices) [6]. 
Some caged neurotransmitters are two-photon sensitive, which allows reaching a 
photolytic reaction with a remarkable spatial resolution and analyzing cellular processes 
with a more exceptional spatiotemporal control [3], as at the level of dendritic spines [4]. 
The use and relevance of caged neurotransmitters have been described in different 
papers [3, 6, 8, 88, 102, 103]. In particular, glutamate and GABA are the most critical 
neurotransmitters mediating excitatory and inhibitory neurotransmission in the Central 
Nervous System, respectively; the balance of these is essential for normal signal 
processing in the brain, and its malfunction has been determined to be a fundamental 
cause of several neurological diseases [80]. In this work of Thesis, one and two-photon 
uncaging are considered for studying the modulations of GABAA receptor responses 
activated by a caged GABA (RuBi-GABA) in the cerebellar granule cells in a novel 


















2.1.1 Caged GABA 
 
Since GABA is the primary inhibitory neurotransmitter in the Central Nervous System 
(CNS), several caged GABA molecules are synthesized and commercially available; 
among these, the most representatives in literature are CDNI-GABA, BCMACM-GABA, 
CNB-GABA, DEAC450-caged GABA, and RuBi-GABA. 
 
CDNI-GABA 
CDNI caged compounds absorb light in the 300-380 nm range, extended beyond 400 
nm; violet lasers can photoactivate these probes [8]. 
It was employed to study GABAA receptor localization to dendritic spine heads, even 
if the function is not entirely understood [8]. 
Also, 720 nm wavelengths photolyze CDNI-caged neurotransmitters during non-linear 
excitation. They are useful for performing two-color uncaging experiments, partnering 
blue light photoactivated caged compounds [8]. 
 
BCMACM-GABA 
BCMACM caged compounds possess a coumarin chromophore linked to the 
biomolecule by an ester bond. Since this bond should be hydrolyzed by intracellular 
esterase, these caged neurotransmitters could be used extracellularly. 
It shows an adequate solubility in aqueous buffer at pH 7.2, is stable for 1 h in the dark 
at room temperature but is gradually hydrolyzed with half-lives of longer than 200 h. 
However, hydrolysis is not found after 2 days, when HEPES is added to BCMACM-
GABA at pH 7.2 and stored at -4 °C in the dark. 
The quantum yield of photolysis is 0.20 for photolysis on irradiation with 390 nm light, 
and the fluorescence lifetime is 760 ps [104].  
 
CNB-GABA 
It is a GABA bond to an α-carboxy-o-nitrobenzyl group, released from this compound 
when exposed to ultraviolet light [105]. It has a quantum yield of 0.02 and photolysis 
half-times of about 1.5 ms [106]. It possesses almost ideal characteristics such as rapid 
photolysis and prolonged spontaneous breakdown [106, 107]. 
However, Gee et al. reported that CNB-GABA behaves as an agonist or antagonist 




Linear and non-linear excitation photo-release this caged GABA; its maximum 
absorption is at about 450 nm towards a one-photon regime. It has a quantum yield of 
0.39; it is soluble and stable in physiological buffer. 
It is excited at 900 nm but is inactive at 720 nm during two-photon uncaging. Therefore, 
it is used for performing two-color uncaging when paired with nitroaromatic caged 
glutamate that is excited at those wavelengths. In this way, the two neurotransmitters can 
be photo-release, with one- and two-photon excitation, around a single spine head of 
neuronal brain slices [6]. 
 
RuBi-GABA 
Ruthenium-bipyridine-triphenylphosphine GABA (RuBi-GABA) is a caged GABA 
photolyzed by visible wavelengths.  
RuBi-GABA is a ruthenium-based photosensor that releases ligands with a single, clean 
and fast photochemical step. It is composed of a ruthenium polypyridine core linked to 







Figure 2.1: GABA release from the photolysis of RuBi-GABA. Copyright © 2008 Rial Verde E. 
M., Zayat L., Etchenique R. and Yuste R. Photorelease of GABA with visible light using an 






Ruthenium-based caged GABA compound provides multiple advantages compared to 
the other available UV-sensitive caged GABA compounds: 
- The inorganic-based photo-release is usually much faster than organic 
approaches [2] 
- The quantum yield of uncaging is higher than the previous standards for GABA 
uncaging [108] 
- The uncaging with visible light results in less scattering (better spatial 
resolution), less phototoxicity (UV wavelengths damage cell DNA and proteins), 
and penetrates deeper into tissue [109] 
- The complex is also active in the two-photon regime (2PE), allowing uncaging 
with IR light using a Ti: Sapphire laser [110] 
RuBi-GABA produces chloride current activating GABAA receptors, and it enables 
receptor and input mapping from various interneuron types. 
The chemical versatility and fast photo-release make RuBi-GABA an ideal caged 

























Patch-clamp is a technique developed by Nobel laureates Erwin Neher and Bert 
Sakmann in 1976. This technique allows electrophysiological studies recording ionic 
currents using glass micropipettes, which determine high resistance in contact with the 
plasma membrane. 
This method enables studying the activity of individual ion channels. It comes from 
the voltage-clamp technique, and it can be applied to any type of excitable cell (i.e., 
neurons, cardiomyocytes and muscle fibers, cell cultures, and tissue slices). 
Cellular processes are studied by measuring the ionic flux by blocking the difference 
of the potential in a small portion (patch) of the plasma membrane. 
While the potential is set constant, the current is measured. Any change in the current 
flow reflects changes in the state of the ion channel opening [111]. 
A 1-2 μm glass micropipette, which adheres to the cell membrane, electrically isolates 
the small area. A seal with a resistance exceeding 10 GΩ, called Gigaohm seal, is created 
with negative pressure. 
After the seal formation, single or whole channel measurements are performed, 
depending on the microelectrode and cell membrane final configuration, the composition 
of the electrolyte solution inside the microelectrode, and the external solution where the 
sample is maintained [112]. 
The patch-clamp is based on the electrical, biological activity due to the movement of 
charges across the plasma membrane, in particular, Na+, K+, Ca2+; the flow of current 






                     (3.1) 
 
 
Where I is the current, V the potential, and R the resistance; the current is proportional to 
the potential. 
Recordings of current changes allow verifying changes in ion channels' opening and 




For obtaining the Gigaohm seal, certain conditions must be fulfilled. In particular, the 
plasma membrane must be clean; no extracellular matrix residues must be present. The 
solutions used in the bath and the micropipette must be filtered before the experiments to 
avoid impurities; the glass microelectrodes must be changed at each measurement. They 
must have resistance between 2 and 5 Megaohms, and the instruments used must be 
placed on an anti-vibration table to ensure mechanical stability and electrically isolated, 








The cell membrane can be assimilated to an equivalent electric circuit RC which 
includes a resistance Rm and a capacitance Cm: the resistance is that offered to the ionic 
flow through the channels, therefore dependent on the number and permeability of the 
different ion channels; the capacitance is related to the dielectric power of the lipid phase, 
that is to the properties of the phospholipid bilayer which allows the separation of positive 
and negative charges, making the plasma membrane assume a behavior similar to a 
capacitor. 
The micropipette is filled with an electrolytic solution and contains a chlorinated silver 
electrode connected to an amplifier. The current flows the membrane in the tip and is 
recorded by the amplifier thanks to negative feedback. This mechanism provides an equal 
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amount of current, but of opposite sign, to the current flowing the cell. Thus, the 
membrane potential can be blocked and the current recorded. 
The patch-clamp can be used in different configurations to follow different purposes: 
i.e., recordings of the activity of a single channel, of channels activated by a ligand, or of 
the total cell currents.  
 
 
3.1.1 Patch-clamp configurations 
 
- Cell-attached 
It is the most straightforward configuration to reach. The microelectrode is brought 
closer to the cell of interest with manipulators. The final approach is favored thanks 
to micromanipulators that allow movements of a few micrometers; when the tip of 
the microelectrode is in correspondence with the cell, slight negative pressure is 
applied to enable the formation of the Gigaohm seal; the cell-attached configuration 
leaves the cell intact and allows the measurement of individual channels [111]. 
 
- Whole-cell patch 
It is obtained by applying negative pressure after reaching the cell-attached 
configuration. The cell plasma membrane inside the tip of the microelectrode 
breaks, the solution inside the micropipette becomes continuous with the cell 
cytoplasm. This configuration is generally the most used and allows the study of 
the response of all the ion channels on the cell membrane [111]. Components in the 
cytoplasm can diffuse into the micropipette, causing significant ion channel 
function effects during measurement. 
In the whole-cell patch-clamp, two recording methods can be considered depending 
on the amplifier configuration: the voltage clamp or the current clamp. In the first 
case, potential pulses are applied, and the ionic membrane current is measured, 
while in the second one, the alterations in the membrane potential are studied after 
the variations in the injected current. Potential pulses of variable duration and 






- Inside-out patch 
After reaching the cell-attached configuration, quickly retracting the 
microelectrode, the part of the membrane in contact with the tip can rupture: a small 
vesicle is formed, which remains attached to the tip of the micropipette. The air 
exposure destroys the vesicle. This lets a portion of the membrane intact on the tip, 
and in particular, the membrane layer inside the cell remains in contact with the 
solution present in the bath, while the outer part is exposed to the internal solution 
of the microelectrode [111]. 
This configuration is useful for conducting studies on a single ionic channel 
function and verifying cytosolic factor effects on a channel [116]. 
 
- Outside-out patch 
It is possible to reach the outside-out configuration by slowly retracting the 
microelectrode tip from the whole-cell configuration. A part of the cell membrane 
is detached and closed on itself due to the phospholipid properties. The outer layer 
of the membrane remains in contact with the bath's external solution and the inner 
part in contact with the solution inside the microelectrode [116]. 
This type of configuration is useful for studying single ion channel functions in 
response to the application of extracellular compounds on the plasma membrane's 
outer layer [111]. 
 
- Perforated patch 
In the microelectrode solution, compounds such as the nystatin and gramicidin 
fungicides are added, determining the formation of ion channels on the plasma 
membrane after reaching the cell-attached configuration. Ions can pass through the 





















Figure 3.2: Representation of the various patch-clamp configurations. Copyright (2007) Wiley. 
Used with permission from Kornreich B.G. The patch clamp technique: principles and technical 







3.2 Optical Microscopy 
 
Microscopy is the use of a microscope for investigating details that cannot be observed 
by the naked eye. 
Microscopes have been developed in the seventeenth century and are currently applied 
in several branches, as in scientific and clinical research and industry. 
Three attributes are crucial: magnification, contrast, and resolution. Magnification is a 
fundamental requirement, resulting in an enlarged image from which the eye's sensory 
elements can collect more information than the smaller naked eye image [117]. Contrast 
is related to the capability to make the details visible to the human eye. Finally, the 
resolution, or resolving power, is the principal characteristic of a microscope, and it is 
classically referred to as the ability to distinguish two near objects as distinct objects 
[118]. 
In optical microscopy, the interaction between the specimen and a beam of 
electromagnetic waves (light) is the critical point; this interaction modifies the beam, 
bringing information about the sample, and is presented as an image. 
 
 





Inadequate equipment or technique may affect the image quality, but the principal 
limitation of light microscopy is due to physics laws and the phenomenon of diffraction 
that occurs whenever a wave motion meets an object [117]. 
Ernst Abbe first elucidated the role of diffraction as the limiting factor in the 
performance of the microscope in 1873 [119] and found that the light, with a wavelength 
λ, traveling in a medium with refractive index n and converging to a spot with half-angle 






     (3.2) 
 
 
nsinα is also referred to as the numerical aperture of an objective lens (NA), a 
dimensionless number that specifies the ability to collect light and resolve fine specimen 
detail at a fixed object distance: a high NA objective can gather more light than one with 
a low numerical aperture. 
 
 
Figure 3.4: Numerical aperture of an objective lens in an optical microscope; α is the half-angle 
of the maximum light cone, n the refractive index of the medium between specimen and lens, F 
is the objective object focal point, 𝐹′ is the objective image focal point, and f is the objective focal 
length. 
 
Light microscopes can be classified: i.e., bright field, fluorescence, phase contrast, 
quantitative phase, and others [120]. 






Fluorescence is a methodology used widely in scientific disciplines. Its detection is 
highly sensitive, and fluorescence imaging can reveal the localization and measurements 
of intracellular molecules, sometimes at the single molecule's detection level. 
 It is a form of luminescence resulting from a three-stage process in particular 
molecules: when illuminated with a specific wavelength, some materials emit light with 
another wavelength; the Jablonski diagram well describes this phenomenon (Figure 3.5). 
 In the first stage (excitation), a molecule (fluorophore) absorbs a photon of energy hνEX 
supplied from an external light source, creating an excited electronic singlet state (S2). 
During the excited state, the fluorophore is susceptible to conformational variations and 
is exposed to interactions with its molecular environment. The S2 energy is partly 
dissipated, resulting in a relaxed singlet excited state S1 (second stage). In an excited 
singlet state, the electron in the excited orbital is paired, by opposite spin, to the second 
electron in the ground-state orbital. Therefore, the electron can return rapidly to the 
ground state with the emission (third stage) of a photon of energy hνEM. 
The fluorescence emission rates are typically 108 s–1; a typical fluorescence lifetime τ, 
the average time between a fluorophore excitation and return to the ground state, is near 
10 ns [121]. 
 
 
Figure 3.5: Simplified Jablonski energy diagram for fluorescence fundamentals. A molecule not 
absorbing energy is confined to a ground state level S0; when a photon excites the molecule, the 
molecule absorbs energy and goes from S0 to S2 excited state level. Finally, the excited molecule 
relaxes to S1 and returns to the S0 ground state level, re-emitting a photon with fluorescence light. 
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The emission energy is generally less than the one of absorption; in fact, fluorescence 
takes place at longer wavelengths or lower energies. This shift, known as Stokes shift 
from Sir G. G. Stokes, who first observed the phenomenon, is caused by the rapid decay 
to the lowest S1 vibrational level [121].  
According to Kasha’s rule and the Valivov rule, a general fluorescence property is that 
the same fluorescence emission spectrum is usually observed independent of the 
excitation wavelength. The photon emission is expected in significant yield only from the 
lowest excited state S1. 
The relaxation to the lowest vibrational level occurs in about 10–12 s; because of this fast 
relaxation, the emission spectra are typically independent of the excitation wavelength. 
Exceptions are molecules, which exhibit two ionization states, each presenting distinct 
absorption and emission spectra. Moreover, some fluorophores emit from the S2 level, 
but this emission is uncommon and mostly not observed in biology [121]. 
 Fluorescence is applied to study various scientific issues; it can supply information on 
a wide range of molecular processes, conformational variations, and binding interactions, 
especially thanks to fluorescence microscopy, which is widespread as a useful tool in 



















3.2.2 Confocal Microscopy 
 
The principle of confocal microscopy was studied by Marvin Minsky and aimed to 
overcome some limitations of fluorescence (widefield) microscopes. 
In a traditional fluorescence microscope, a beam of light, provided by a xenon or 
mercury bulb, is filtered by an excitation filter; a dichroic mirror directs the light to the 
whole specimen, which is illuminated (widefield). The emitted fluorescence light from 




Figure 3.6 Scheme of a fluorescence microscope. 
 
 
The fluorescence concepts also apply to confocal microscopy; the significant 
differences are the excitation source (a bright point source such as a laser), a sequential 
scanning method of the illumination point source, and the detector of the emitted light is 
a photomultiplier tube (PMT). 
The light out of focus is rejected thanks to a pinhole aperture: the light that reaches the 
detector comes only from the “confocal point” in the specimen where the excitation light 
is focused. 
The image is created pixel by pixel by scanning the confocal excitation and detection 
point across the specimen and recording the fluorescence at each point. The laser and 
pinhole remain stationary; a pair of oscillating orthogonal mirrors optically direct the laser 






Figure 3.7: Laser scanning confocal microscope (LSCM) fundamental elements. The laser light 
reaches the specimen by a dichroic mirror and scan mirrors; the laser is scanned across the sample, 
the emitted fluorescence light is descanned by the scan mirrors, and transmitted by the dichroic 
mirror. It passes across an emission filter; it is focused onto the pinhole (adjustable confocal iris) 
and arrives at the photomultipliers. Extra dichroic mirrors are added to separate fluorescence 
wavelengths. Copyright © 2014 Cold Spring Harbor Laboratory Press. Used with permission 
from Sanderson M. J., Smith I., Parker I., Bootman M. D. (2014). Fluorescence microscopy. Cold 
Spring Harb Protoc, 2014 (10): pdb.top071795. doi: 10.1101/pdb.top071795 [122]. 
 
 
The image formation is produced using the image of a point, the point spread function 
(PSF), and determined the level of detail observed [123]. The PSF depends on the 
wavelength and the numerical aperture of an objective; it is a measure of the resolving 
power: narrow PSF, better in the resolution, even if aberrations of the optical setup may 
distort the PSF. 
Ideally, the PSF is the 3D diffraction pattern of light emitted from an infinitely point 
source object and transmitted to the image plane through a high NA. The emitted light is 
collected by the objective and focused on a corresponding point image plane. At the focal 
point, the light waves converge and interfere and produce a diffraction pattern of 
concentric rings of light surrounding a central bright disk; the NA determines the radius 







        (3.3) 
 
The Rayleigh criterion declares that it is only possible to resolve a pair of sources if 
the two diffraction patterns' central peaks are no closer than the radius of the Airy disk. 
 
 
3.2.3 Two-Photon Microscopy 
 
The confocal microscope improves spatial resolution by forming the image through a 
pinhole in front of the detector, which allows avoiding the emission light out of focus 
[86]. However, LSCM has a limitation in-depth penetration into tissues due to the use of 
short wavelength light produced by scattering and absorption [122]. Two-photon 
microscopy overcomes this limitation by employing longer wavelengths, which are not 
only less scattered by the specimen but may also not excite background autofluorescence 
[124]. 
Two-photon excitation (2PE) is a non-linear process made possible by the 
simultaneous absorption of two photons; the total energy must be sufficient to reach a 
transition to an excited electronic state [124]. 
This phenomenon occurs with very high photon density and is achieved when the laser, 
with a pulse duration (τp) of about 100 fs at a repetition rate (fp) of about 80 MHz [86], is 





Figure 3.8: Simplified Jablonski diagrams for one- (left) and two-photon (right) fluorescence. 
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       (3.4) 
 
Where p0 is the laser power, δ the two-photon cross-section, τp the pulse duration, fp the 
pulse repetition rate, NA the numerical aperture, ℏ the Planck quantum of action, c the 
speed of light and λ the wavelength [86]. Hence, the photon density increases as a 
quadratic function approaching the focal point, the fluorescence is strictly stimulated in 





Figure 3.9: Excitation volume of one- (left) and two-photon (right) process. When the blue light 
is used for exciting a sample during the one-photon regime, a double cone of green fluorescence 
is produced. In comparison, near-infrared light is used during 2PE, and non-linear signal 
production is localized to the proximity of the focal spot. Copyright (2005) Wiley. Used with 
permission from Helmchen F., Denk W. Deep tissue two-photon microscopy. Nat Methods, 





Figure 3.10: Two-Photon microscope fundamental elements. The detectors do not require 
pinholes or focused images and are located immediately below the objective. Copyright © 2014 
Cold Spring Harbor Laboratory Press. Used with permission from Sanderson M. J., Smith I., 
Parker I., Bootman M. D. (2014). Fluorescence microscopy. Cold Spring Harb Protoc, 2014 (10): 
pdb.top071795. doi: 10.1101/pdb.top071795 [122]. 
 
 
Multiphoton absorption, compared to LSCM, offers some advantages for commonly 
fluorescent probes, the main of which are more penetration into thick tissues and 
generally less phototoxicity due to the use of near-infrared wavelength range (700-1000 
nm) with visible spectral range emission. Also, it allows highly localized photo-
manipulations, i.e., photobleaching and photolytic release of caged compounds, within 
femtoliter volumes [123]. 
Moreover, the capability to reject out of focus signal gives a resolution increase of 
about √2 compared to the diffraction-limited spot of excitation light. It is not a real 
genuine superresolution; in fact, the double wavelength causes an increase of diffraction 








Chapter 4: Materials and methods 
 
4.1 Cell cultures 
 
The cell cultures allow the growth of cells in vitro from tissues and biological fluids. 
In suitable supports such as plates, flasks, and bottles, the cells are kept alive thanks to 
medium, serums, and metabolites necessary for their growth. 
They have different advantages: they are simplified and reproducible systems that 
enable several studies in different fields (i.e., cellular, molecular biology, pharmacology 
and toxicology, genetics, oncology) with lower costs than animal experimentation and 
controlled chemical, physical, and physiological conditions. On the other hand, they do 
not allow reproducing the complexity of the organism in toto. It is difficult to correlate 
the concentrations in vitro with those in vivo, the substances used can interact with the 
culture medium, and the exposure conditions to the various metabolites differ from the in 
vivo system [126]. 
Cell cultures involve the use of a series of actions aimed to maintain sterility, avoiding 
contamination with microorganisms (more typically bacteria, viruses, fungi, and 
mycoplasmas): stoves, UV rays, and autoclaves are used for sterilizing the laboratory 
material, and laminar biological safety cabinet for avoiding contamination during the cell 
manipulations. 
Cell cultures can be adherent, as monolayer cells, or in suspension. They may have a 
finite life (limited expansion over time), continuous (indefinite replication), clonal 
(derived by mitosis from a single cell). The growing trend of a cell culture follows three 
phases characterized by the adaptation of the cell culture (primary culture), cell growth 
(expansions that allow originating subcultures), and senescence (decay), or development 




Figure 4.1: Trend of a cell culture vs. time; phase I represents a primary culture; phase II, in 
which it is possible to obtain subcultures, indicates the cell growth, phase III is the decay or 
development of a cell line. 




The cell culture growth medium must ensure the supply of all the necessary substances 
and survival stability through the control of temperature, pH, and osmolarity. For this 
reason, it is crucial to choose a suitable culture medium, possibly enriched with serum, 
glutamine, and antibiotics. CO2 incubators maintain the correct temperature and CO2 
concentration for guaranteeing the cell pH control. 
The medium is necessary to reproduce an environment as similar as possible to that in 
vivo: they contain inorganic salts, energy molecules such as glucose, essential and non-
essential amino acids for protein synthesis, vitamins, water, and trace elements. 
Some medium compounds maintain an optimum of pH: sodium bicarbonate (NaHCO3) 
is very used for its economical and not very toxic behavior, or HEPES (4-(2-
Hydroxyethyl)piperazine-1-ethanesulfonic acid), a non-toxic synthetic molecule. Also, a 
compound, phenol red, is added, which allows a visual pH control. Depending on the pH 
value, phenol red changes color: at physiological pH, the medium appears red-orange; it 
turns yellow at low pH and red-violet for high pH. 
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It is usually added 5-20% of serum (bovine, equine, human) to the culture medium that 
contains growth (EGF, FGF, PDGF) and adhesion factors, hormones, and lipids [127]. 
Fetal bovine serum (FBS) and newborn bovine serum (NCS) are the most used. However, 
they can be a source of contamination, so they are tested to check for the absence of 
mycoplasmas and common bovine viruses. 
The addition of antibiotics (i.e., penicillin-streptomycin and gentamicin) is common 
to avoid bacterial contamination, but they led to an increase in the selection of antibiotic-
resistant bacterial strains; it becomes a good practice to use antibiotics for primary cell 
cultures or for "precious", rare cell cultures. 
 
 
4.1.1 Cerebellar granule cell primary cultures 
 
In the initial phase, it is necessary to sterilize the laboratory material, prepare the 
culture medium, and the solutions for the cerebellar granule cell isolation. After that, it is 
possible to remove the cerebella. 
Sterilize in an oven for 30-60 minutes at 180 °C 1-2 trypsinization flasks, cylinders, 
beakers, tweezers, scissors, and in an autoclave at about 2 atm for 30 minutes Milli-Q 
water, tips for P1000 and P200, Pasteur pipettes with and without filter, 1.5 ml Eppendorf. 
Prepare the culture medium: 90% BME (Basal Medium of Eagle) culture medium, 10% 
FCS, 100 μg/ml of glutamine, 100 μg/ml of antibiotics (gentamicin), and 25 mM KCl. 
The KCl must be filtered with a 0.2 µm Millipore filter after dissolving it with a small 
part of the medium. 
The table below shows an example of the compounds’ composition and quantity used 













Compounds 100 ml 
BME 90 ml 
FCS 10 ml 
Glutamine 1 ml 
Gentamicin 1 ml 
KCl 25 mM 0.13 g 
 
Table 4.1: Medium components for cerebellar granules and relative quantities on 100 ml. 
 
 
During the cell preparation, it is necessary to use five solutions derived from 10x Krebs 
salts solution (basic solution). The composition is illustrated below. 
 
Krebs Salt Solution 10x 500 ml 100 ml 
NaCl 53.3 g 7.07 g 
KCl 1.8 g 0.36 g 
KH2PO4 0.83 g 0.166 g 
Glucose 12.85 g 2.57 g 
NaHCO3 10.7 g 0.214 g 
Phenol Red 0.072 g 0.015 g 
 












Sodium bicarbonate (NaHCO3) is added on the day of cell preparation to prevent pH 
alterations, and the solution is brought to a volume of 100 ml with sterile Milli-Q water. 
The 5 solutions used during cell preparation are listed below: 
- Solution 1: 100 ml Krebs salt solution + 300 mg BSA (bovine serum albumine) + 
800 μl di MgSO4 (3.82% in Milli-Q water) 
- Solution 2: 24 ml solution 1 + 1 ml trypsin (6.25 mg/ml) 
- Solution 3: 13 ml solution 1 + 1 ml DNAse (1.2 mg/ml) + 1 ml trypsin inhibitor (7.8 
mg/ml) + 150 μl MgSO4 (3.82% in Milli-Q water). 
- Solution 4: 21 ml solution 1 + 4 ml solution 3 
- Solution 5: 12.5 ml soluzione 1 + 100 μl MgSO4 (3.82% in Milli-Q water) + 15 μl 
CaCl2 (1.2% in in Milli-Q water) 
 
All solutions are filtered with a sterile 0.2 μm Millipore filter: 10 ml of solution 1 in a 
50 ml Falcon, 10 ml of solution 2 in a 15 ml Falcon, 5.5 ml of solution 3 in a 50 ml Falcon, 
10 ml of solution 4 in a 50 ml Falcon and 3 ml of solution 5 in a 15 ml Falcon. 
The cerebella are obtained from 6-8 day Sprague-Dawley rats; the cerebella are 
removed, deposited in a Petri dish containing DPBS filtered with a 0.2 μm Millipore filter, 
and the meninges are eliminated with the fine tweezers (n.5 sa, DMR). 
The cerebella are placed side by side on a plastic disc and cut with the Tissue Chopper 
(The Mickle laboratory engineering CO.LTD): a cut is made along the longitudinal axis, 
the disc is rotated 90° to allow its transversal cutting. 
They are then transferred to the Falcon containing 10 ml of solution 1 with a Pasteur 
pipette with filter and centrifuged at 1000 rpm for 10-15 seconds. 
The supernatant must be aspirated, and 10 ml of solution 2 containing trypsin, an 
enzyme that promotes tissue dissociation, is added to the sediment; the Falcon must be 
stirred with a rotating movement to resuspend all the cells, the contents are poured into a 
trypsinization flask which is incubated in a thermostated bath at 37 °C for 15 minutes 
with a stirring of 120-150 movements per minute. 
10 ml of solution 4 are added to block the trypsin's action and, after stirring with rotary 
movements, centrifuge at 1000 rpm for 10-15 seconds. 
The supernatant is aspirated, and a Pasteur of solution 3 is added. The pellet is 




The solution is transferred to a 15 ml Falcon and left to settle for 10-15 minutes; the 
supernatant is mixed in solution 5, the sediment is again resuspended with a Pasteur of 
solution 3 and then transferred to solution 5. 
It is left to settle for 10 minutes, with a Pasteur the supernatant containing the granules 
is brought into a 15 ml Falcon, it is decanted for 5 minutes, and if the solution is clear, 
the supernatant is centrifuged at 1500 rpm for 5 minutes. 
The supernatant is aspirated, and 5-6 ml of the culture medium is added to the sediment 
to resuspend the cells. 
In a 1.5 ml Eppendorf, 900 μl of culture medium and 100 μl of the cell suspension are 
combined to proceed with cell counting and then plating; 20 μl are taken from the 
Eppendorf and transferred to the Thoma chamber: the cells in the upper and lower 
chambers are counted under the microscope and, after averaging the two counts, 5 zeros 
are added to the final value to obtain the number of cells/ml. 
1.5-2.5 · 106 cells/well are plated; to calculate the amount of cell suspension to add in 
each well, set the proportion based on the count. 
Each Petri dish has previously been treated with 10 μg/ml poly-L-lysine: the polylysine 
is prepared in a concentrated solution (10x) containing 1 mg/10 ml Milli-Q water; the 
sterilized solution is kept at –20 °C. 
Petri dishes must be left for 15-20 minutes under UV rays, then the polylysine is aspirated, 
and the plates are left to dry for 30 minutes, partially covering with the lids; for plating 
the cells on slides, the coverslips are first soaked in a solution with detergent, sonicated, 
dried and left in absolute alcohol for a few hours. 
The slides are sterilized by passing them over a flame and putting in the Petri Dish 
before treating them with polylysine. 
18 hours after plating, within 24 hours, 10 μM AraC (Cytosine Arabinoside) is added; 
it is an antimitotic prepared on the day of use. In essence, 1-2 mg AraC is weighed and 
diluted according to the proportion of 1.1 mg/1 ml to obtain a concentration of 4 mM. 
The solution is sterilized with a 0.2 μm Millipore filter, diluted with 1/10 medium to 
obtain a concentration of 400 μM, and added to the culture according to the proportion 
50 μl/ 2 ml. 
48 hours after plating, the culture medium is refreshed: the old culture medium is 
aspirated and replaced with a new one prepared on the day of collection. 







4.2.1 External and internal solutions 
 
The cells are kept in an external solution; the microelectrode is filled with an internal 
solution that mimics the intracellular liquid composition. 
The composition of the solutions is shown in the following tables: 
 
 




NaCl 58.44 135 7.8894 
KCl 74.55 5.4 0.4026 
CaCl2 147 1.8 0.2646 
MgCl2 203.3 1 0.2033 
Hepes 238.3 5 1.1915 
Glucose 180.2 10 1.802 
 
Table 4.3: Standard external solution composition 
 




Internal Solution Molecular Weight mM g/100 ml 
KCl 74.55 142 1.0586 
MgCl2 203.3 2 0.0406 
Hepes 238.35 10 0.2383 
EGTA 380.35 2 0.0760 
ATP 551.1 3 0.1653 
 
Table 4.4: Internal solution composition 
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The internal solution is brought to pH 7.3 with 1 M and 0.1 M Tris base. It is kept at -20 
°C in aliquots of 5-6 ml; on the day of use, it is thawed and kept in ice to avoid hydrolysis 
of the ATP, which could compromise the success of the experiments. 
 
 
4.2.2 Solutions employed during the experiments 
 
The solutions used during the measurements are: 10 μM RuBi-GABA, 1 μM 
Antisecretory Factor, 10 μM RuBi-GABA + 1 μM Antisecretory Factor, 10 μM RuBi-
GABA + 1 mM Furosemide, and 10 μM RuBi-GABA + 1 mM Furosemide + 1 μM 
Antisecretory Factor. 
 
- 10 μM RuBi-GABA 
A 10 mM RuBi-GABA solution (stock solution) is prepared by dissolving 0.01 g 
RuBi-GABA in 1.08 ml of sterile Milli-Q water. 50 μl are taken from this stock 
solution and brought to a volume of 50 ml with the external solution to reach the 
concentration of 10 μM RuBi-GABA. 
 
- 1 μM Antisecretory Factor (AF-16) 
A 100 μM AF-16 stock solution is prepared by dissolving 0.003 g Antisecretory 
Factor in 17 ml of the external solution; 500 μl are taken from this stock solution 
and brought to a volume of 50 ml with the external solution to reach the 
concentration of 1 μM. 
 
- Solution with 10 μM RuBi-GABA and 1 μM Antisecretory Factor (AF-16) 
50 μl of 10 mM RuBi-GABA stock solution and 500 μl of 100 μM AF-16 were 
diluted in 50 ml of the external solution to obtain the concentration of 10 μM RuBi-
GABA and 1 μM AF-16. 
 
- Solution with 10 μM RuBi-GABA and 1 mM Furosemide 
A 10 mM Furosemide stock solution is prepared by dissolving 0.1654 g Furosemide 
in 50 ml of the external solution; 5 ml are taken from this stock solution and added 
with 50 μl of 10 mM RuBi-GABA stock solution. The solution was brought to a 
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volume of 50 ml with the external solution to obtain 1 mM Furosemide and 10 μM 
RuBi-GABA concentrations. 
 
- Solution with 10 μM RuBi-GABA, 1 mM Furosemide and 1 μM Antisecretory Factor 
(AF-16) 
5 ml are taken from the 10 mM Furosemide stock solution and added with 50 μl of 
10 mM RuBi-GABA stock solution and 500 μl of 100 μM AF-16. The solution was 
brought to a volume of 50 ml with the external solution to obtain 1 mM Furosemide, 
10 μM RuBi-GABA, and 1 μM AF-16 concentrations. 
 
 
4.3 Preparation of the micropipettes 
 
Essential for the success of the experiments is the possibility of using micropipettes 
capable of originating a Gigaohm seal; borosilicate glass capillaries are used for this 
purpose, which not only allow the achievement of a high-strength seal with the cell 
membrane but also cause little background noise during recording. 
The capillaries are washed in acetone, rinsed with deionized or milli-Q water, dried in 
an oven at 80 °C on aluminum foil to eliminate any impurities that can interfere with the 
formation of the seal; subsequently, they are subjected to a series of phases which foresee 
the heating and the draft by a vertical puller (P-30 model, Sutter Instruments Co) for the 
realization of micropipettes. 
The capillary is heated and pulled to reach a diameter of 200 μm; after being 
repositioned, it is heated again, withdrawn, and separated in the two microelectrodes. The 
parameters that define the draft and the two heating phases are fixed to obtain many 










4.4 Experimental apparatus 
 
The patch-clamp instrumentation is placed on an anti-vibration table, with compressed 
air shock absorbers, to prevent any mechanical vibrations that could avoid the seal 
formation. 
The setup used for the experiments consists of an inverted three-channel laser scanning 
confocal microscope (Leica TCS SP5, Leica Microsystems, Germany) equipped with 458-
, 476-, 488-, 514-, 543-, and 633-nm excitation lasers and a plan-apochromatic oil 
immersion objective × 63/1.4. 
LAS AF (Leica Microsystems, Germany) was the software used for acquiring the 
images before and after the uncaging confirming the absence of relevant cell 
displacements, using a 633 nm laser source coupled to a photomultiplier tube. 
The two-photon excitation and uncaging were performed with a Ti: Sapphire laser 
(Chameleon II, Coherent Inc., Santa Clara, CA, USA). This laser operates with pulses of 
100 fs at the repetition frequency of 80 MHz. 
The laser power was measured at the objective focal point by a PM100A power meter 
(Thorlabs Inc., Newton, NJ, USA), and the laser stability was checked after considering a 
balance between pulse width and power performances, suggesting the utilization of 750 
nm. 
FRAP Wizard Leica was used to set up the bleach point in terms of coordinates, laser 
power, and exposure time during the uncaging experiments. 
On the microscope stage is placed a chamber for the samples connected to a system of 
free fall perfusions by a manipulator (MP-225, Sutter Instrument, Novato, CA, USA) used 
for approaching the tip of the micropipette to the cell, and an electrode holder formed by 
a Teflon body and an opening for positioning the chlorinated silver electrode; on it, thanks 
to a screwed plastic cap, the glass microelectrode, containing the internal solution, is 
inserted, and a silicone tube is connected for applying negative pressure during the seal 
formation. 
An amplifier (Axopatch 200B, Axon Instruments, USA) allows the reading of the 
current values, the filtering of the background noise, and other operations such as the 
compensation of the electrode resistance, the cell capacity, and the series resistance; this 
amplifier consists of two units, a pre-amplifier, and a controller. 




The computer and software are used to monitor the experiment, store the data, and 
analyze them. 
The software considers the conversions applied and displays an appropriate scale for 
the recorded current represented by a trace on the monitor. 
The acquisition and analysis of the currents were carried out using the pClamp software 
(Axon Instruments, USA), particularly version 10 of Clampex and Clampfit. 
 
 
4.5 Electrophysiological measurements 
 
The electrophysiological measurements were performed on rat cerebellar granule cells 
in culture to verify the modulation of the currents activated by the uncaging of RuBi-
GABA using the patch-clamp technique in whole-cell configuration. A protocol was 
followed that took into account the currents activated by the passage of chloride ions 
through the GABAA channel receptor. 
The slide with the samples was placed in the bath chamber with an external solution; 
the glass microelectrode was brought closer to the neuron's cell membrane for the 
recording using macro and micromanipulators and, creating negative pressure, a seal was 
formed to achieve the cell-attached configuration. 
The amplifier was set to the voltage-clamp configuration; a suitable potential was fit 
for the current measurements activated by the GABA (typically -80 mV), and the plasma 
membrane was then broken with a slight suction to reach the whole-cell configuration. 
The washing solution (external solution), the caged compound solutions, and the 
pharmacological molecules flow thanks to the perfusion system. 
Before carrying out the measurements, it was checked that the compound did not 
determine a GABAA receptor response before the uncaging. 
The typical experiment consists of measuring the 10 μM uncaged RuBi-GABA 
activated current on the same cell in different experimental conditions. The current 
activated by uncaged RuBi-GABA alone is compared with that activated by uncaged 
RuBi-GABA with the pharmacological compounds. 
The various measurements are interspersed by washing the cell with the external 






Chapter 5: Results 
 
Initially, it was checked that photolyzed RuBi-GABA determined the activation of 
GABAA receptors. When 10 μM RuBi-GABA is uncaged, a maximum current value 
(peak) is recorded, reflecting a population of GABAA ionotropic receptors associated with 
Cl– channels. After the photoexcitation, the measured current returns to the original value 
(Figure 5.1). 
 
Figure 5.1: Current (pA) versus time (s). Current trace recorded at a holding potential V 
= -80 mV during the photoactivation of 10 μM RuBi-GABA with 1PE (458 nm, 100 ms, 
6.7 μW). 
 
Moreover, experiments were performed to verify that uncaged RuBi-GABA directly 
acted on GABAA receptors using the competitive antagonist bicuculline. 
1 μM RuBi-GABA was photolyzed to activate GABAA receptors (Figure 5.2 left trace); 
after the administration of 20 μM bicuculline, which competes for the GABA site, no 
relevant current alterations were recorded even if 1 μM RuBi-GABA was uncaged 
(Figure 5.2 right trace). 





Figure 5.2: Current (pA) versus time (s). Current traces recorded on the same cell during the 
uncaging of 1 μM RuBi-GABA by 1PE (458 nm, 100 ms, 6.7 μW) at a holding potential V =  -
80 mV before (a) and after the administration of 20 μM bicuculline (b). 
 
For characterizing the uncaging technique, critical parameters that could influence the 
electrophysiological measurements have been extensively explored and correlated in a 
temporally and spatially confined way: one and two-photon excitation (1PE and 2PE), 
laser power, exposure time, X-, Y-, Z- distance uncaging point from the target cell, 
different holding potentials. 
For each parameter variation, it was decided to perform experiments on the same cell 















5.1 1PE, 2PE, Laser Power 
 
The excitation volumes of one and two-photon regimes are considerably different. 
During the one-photon process, the caged molecules are photolyzed along the entire laser 
optical path, and the amount of photo-released compound, conserved plane by plane 
following the distribution of the photon density, is proportional to the light absorbed in 
each plane. 
The uncaging with 2PE is a process spatially localized due to the simultaneous absorption 
of two photons that results in a volumetrically confined event. 
Therefore, experiments were performed to evaluate the effects of these distinct processes, 
changing the laser power for both 1PE and 2PE. 
The current peaks, measured during both 1P and 2P uncaging after GABAA receptor 
activation, increase, spanning from low to high laser power, though the localized volume 





Figure 5.3: Current (pA) versus time (s). Typical traces of chloride current peaks evoked by 10 
μM RuBi-GABA uncaged at V = -80 mV by using different laser power for 1PE (458 nm, 100 






When the laser power rises, the amount of uncaged GABA increases, resulting in an 
increase of the activated GABAA receptors until reaching a saturation because of the 
photoactivation of all molecules in the excitation volume. 
The experiments were repeated by doubling the RuBi-GABA concentration to ensure 
it was not due to a receptor saturation effect. 
Figure 5.4 A and B report the curves for 1PE and 2PE, respectively, of the normalized 
current peak values as a function of the laser power for 10 µM and 20 µM RuBi-GABA. 
The plateau is reached for the same relative laser power, and the curves show the same 
trend. Consequently, the peak current saturation is due to a limited number of uncaged 
molecules, not to the receptor saturation; otherwise, saturation should occur at a lower 




Figure 5.4: Current versus laser power. Current peaks (normalized values to the peak current 
value evoked using 4.9 μW for 1PE and 77.3 mW for 2PE) evoked by the uncaging of 10 μM (red 
squares) and 20 μM (black triangles) RuBi-GABA using different laser power for 1PE (458 nm, 









5.2 Exposure Time 
 
During 1P or 2P processes, the photolyzed molecules spread out of the excitation 
volume and diffuse in the solution. An exposure time longer than this diffusion time 
involves a replacement by new caged molecules that come into the excitation volume, 
becoming photoactivated. 
Therefore, a “cloud” of uncaged molecules shapes around the uncaging volume for long 
exposure time. 
Figure 5.5 A and B show the experiments performed, at least on 4 cells per session, 
changing the exposure time. 
 
 
Figure 5.5: Current (pA) versus time (s). Typical traces of chloride current peaks evoked by 10 
μM RuBi-GABA uncaged at V = -80 mV using different exposure time for 1PE (458 nm, 9.36 
µW) (A) and 2PE (750 nm, 125 mW) (B) on the same cell. 
 
The current peak intensity (Figure 5.5 A, Figure 5.6 A) and the time of decay (Figure 
5.6 C) rise to a plateau value, raising the exposure time during 1PE. The full width at half 
maximum (FWHM) shows a linear trend (Figure 5.6 E). 
On the other hand, the current peak intensity and the time of decay do not change 
during 2P uncaging (Figure 5.5 B, Figure 5.6 B, D), but the FWHM linearly increases 








Figure 5.6: Chloride current peaks, normalized to the current measured for the lowest exposure 
time (1 ms), evoked by 10 μM RuBi-GABA uncaged at V = -80 mV using different exposure 
time during 1P uncaging (458 nm, 9.36 µW) (A) and 2PE (750 nm, 125 mW) (B) on the same 
cell. Time of decay (τ) versus the exposure time for 1PE (458 nm, 9.36 μW) (C) and 2PE (750 
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nm, 125 mW) (D). Full width at half maximum (FWHM) as a function of exposure time for 1PE 
(458 nm, 9.36 μW) (E) and 2PE (750 nm, 125 mW) (F). The data are collected on at least 4 cells, 
and each value is estimated by calculating the mean ± SEM. 
 
 
5.3 X, Y, Z Distance from the target cell 
 
Changing the distance of the uncaging point along the X-Y plane (Figure 5.7 A), the 
peak current intensities decrease both for 1PE and 2PE (Figure 5.7 B, C, D); in particular, 
when the uncaging occurs in the confined volume of 2PE (Figure 5.7 B, black circles), 
the current peaks exhibit a faster decrease compared to 1PE (Figure 5.7 B, red squares) 
as the distance in X-Y increases. 
 
Figure 5.7: Uncaging points at different distances from the target along the X-Y plane (A). 
Current peak values, normalized to the distance 0 μm far from the cell, versus the distance after 
the uncaging of 10 μM RuBi–GABA at V = -80 mV with 1PE (458 nm, 100 ms, 9.36 μW-red 
squares) and 2PE (750 nm, 100 ms, 77.3 mW-black circles) (B). Current peaks recorded for the 
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uncaging points reported in (A) for 1PE (458 nm, 100 ms, 9.36 μW) (C) and 2PE (750 nm, 100 
ms, 77.3 mW) (D). 
 
The amount of photolyzed RuBi-GABA that binds the receptors may diverge because 
of the isotropic diffusion of uncaged molecules, and when the distance increases, the rise 
time grows (Figure 5.8). 
If the diffusion dynamics of the uncaged molecules is approximated as the diffusion 










       (5.1) 
 
C is the concentration of the molecules, D the diffusion coefficient, x the distance from 
the point source, t the time, and A an arbitrary constant. 
Therefore, the current rise time was fitted with equation 1 (Figure 5.8). At a temperature 
of 25 °C and viscosity of 1 mPa s, the diffusion coefficient analyzed for four distance 
values of four different cells, (6 ± 3) 10-10 m2 s-1, agrees with the theoretical one estimated 
for GABA [11].  
 
 
Figure 5.8: Rising current peak (black line) fitted (red line) with equation 1 versus the time 




The current peaks recorded during 1PE (458 nm, 100 ms, 9.36 μW) and 2PE (750 nm, 
100 ms, 77.3 mW) at different uncaging Z-distances (Figure 5.9) show a distinct behavior. 
The measured current peak remains constant within a distance of about 10 µm, a 
distance comparable to a granule cell size, from the coverslip surface, then it linearly 
decreases during 2PE (Figure 5.9 black circles).  
On the other hand, during 1PE, the current peak increases, and, after that, it remains 
constant (Figure 5.9 red squares) [11]. 
 
 
Figure 5.9: Current peak values, normalized to the distance Z=0 μm far from the coverslip 
surface, versus the Z-distance during the uncaging of 10 μM RuBi–GABA at V = -80 mV with 














5.4 Current-Voltage Curves 
 
Experiments were performed at different holding potentials for evaluating possible 
different effects on current peak values using the neurotransmitter GABA and caged 
compound RuBi-GABA. 
Figure 5.10 reports the current-voltage (I-V) curve recorded with 10 µM GABA and 
10 µM RuBi-GABA, applying a voltage bias from -60 mV to +60 mV with steps of 20 
mV. 
10 µM GABA curve shows an ohmic trend, as previously described by Robello et al. 
1994 [128]; the I-V curve recorded after the uncaging of 10 µM RuBi-GABA (1PE, 458 
nm, 9 µW, 100 ms) has an ohmic trend comparably to that of GABA [11]. 
 
Figure 5.10: Current-voltage curves. The current peak values, normalized to the current peak 
recorded for -60 mV, are measured using 10 μM GABA (red squares) and after uncaging 10 μM 









5.5 RuBi-GABA dose-response 
 
Different RuBi-GABA concentrations were tested: 1, 10, 20, 50, 100 µM. 
Hence, a dose-response graph was constructed, reporting the RuBi-GABA concentrations 
on the X-axis and the peak current on the Y-axis (Figure 5.11) [11]. 





𝑛      (5.2) 
 
Where Ip is the dependent variable corresponding to the current peak values, Imax is the 
maximum current peak value, C is the concentration (independent variable), n the Hill 
coefficient, Ka a constant. The results were: Ka = 1.98 µM , Imax = 247 pA, and a Hill 
coefficient of 1.1. 
 
 
Figure 5.11: RuBi-GABA dose-response curve measured using 2PE (750 nm, 100 ms, 45 mW, -
80 mV). Peak current (pA) versus RuBi-GABA concentrations (µM). The vertical bars represent 
the SEMs. The curve fit is calculated according to the Hill equation 𝐼𝑝 = 𝐼𝑚𝑎𝑥 ∙ (𝐶





5.6 RuBi-GABA and pharmacological molecules 
 
After the characterization of the main physical parameters that occur during the 
uncaging of the caged compound RuBi-GABA, it was decided to evaluate the effects of 
the pharmacological molecule Antisecretory Factor (AF-16) in well-defined areas of the 
neuron: soma, the growth cone, and neurites. 
The results of the Antisecretory Factor effect on the modulation of the current activated 
by GABA on rat cerebellum granule cells were previously tested and reported in the paper 
Bazzurro et al. 2018: measurements of currents activated by 10 µM GABA after the 
pretreatment with Antisecretory Factor showed an increase in the current induced by 
GABA [12]. 
For these new sets of experiments with RuBi-GABA and Antisecretory Factor, 2PE 
was considered the most suitable uncaging parameter, precisely due to its characteristic 
that endures the photo-release of molecules in a confined volume. Hence, it allows the 
study of the Antisecretory Factor response on a limited number of GABAA receptors in a 
defined region and, consequently, how its action changes in a precise, specific, and 
limited neuron area. 
Firstly, the current induced by the uncaging of 10 µM RuBi-GABA was checked. After 
the incubation for 3 minutes with Antisecretory Factor, RuBi-GABA was uncaged 
combined with AF-16 (Figure 5.12). 
 
Figure 5.12: Current (pA) versus time (s). (a) Current trace after the uncaging of 10 μM RuBi-
GABA (750 nm, 100 ms, 30 mW, -80 mV), (b) pretreatment for 3 minutes with 1 μM AF-16, (c) 





The response increases after the treatment with Antisecretory Factor, just like in the 
results obtained with GABA. 
Since the preliminary results confirmed the past ones, experiments were performed in 




















Figure 5.13: Uncaging points on soma (red asterisk), growth cone (yellow asterisk), and neurite 
(green asterisk) of a cerebellar granule cell. 
 
 
The uncaging of RuBi-GABA combined with AF-16 after the treatment with 
Antisecretory Factor for 3 minutes increases the current (facilitating action) due to the 














Figure 5.14: Example of chloride current traces evoked by 10 μM uncaged RuBi-GABA (750 
nm, 100 ms, 30 mW, -80 mV) on soma (A), growth cone (B), and neurite (C) on the same cell: 
(a) Current trace after the uncaging of 10 μM RuBi-GABA, (b) pretreatment for 3 minutes with 
1 μM AF-16, (c) current measured after the photo-release of 10 μM RuBi-GABA in combination 





The effect induced by the Antisecretory Factor was calculated by the percentage effect 





) ∙ 100     (5.3) 
 
 E% ± SEM n 
Soma (37 ± 3) % 25 
Cone (27 ± 4) % 13 
Neurite (40 ± 3) % 14 
 
Table 5.1: Effect of AF-16 on uncaged RuBi-GABA induced current after the pretreatment for 3 
minutes of the Antisecretory Factor on soma, growth cone, and neurite. The significance of the 
result is indicated for each data series. 
 
 Statistical Significance 
Soma-Cone p < 0.05 
Soma-Neurite n.s. 
Cone-Neurite p < 0.05 
 
Table 5.2: Statistical significance of the differences in the effect of 1 µM AF-16 on soma-cone, 
soma neurite, cone-neurite. Statistical comparisons were analyzed with Student’s t-test. 
 
A series of experiments were carried out on the soma, using the selective 
pharmacological molecule furosemide, for understanding which receptor subtypes may 
be involved in the Antisecretory Factor mechanism of action. Furosemide is a selective 
blocker for the α6 subunit of GABAA receptors. 
Figure 5.15 reports the traces of the current measurements. 
Firstly, the current induced by the uncaging of 10 µM RuBi-GABA was verified 
(Figure 5.15 A (a)); after the incubation for 3 minutes with Antisecretory Factor (Figure 
5.15 A (b)), RuBi-GABA was uncaged combined with AF-16 (Figure 5.15 A (c)). 
As expected, the response increases after the treatment with Antisecretory Factor. 
On the same cell, RuBi-GABA was uncaged in combination with 1 mM Furosemide 
(Figure 5.15 B (c)) after a wash-out for 1 minute with the external solution (Figure 5.15 
B (b)). 
In this case, the current peak decreases because of the blocking of α6 receptor subtypes. 
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Finally, after a new treatment with antisecretory factor for 3 minutes (Figure 5.15 
C(b)), RuBi-GABA was uncaged combined with 1 µM AF-16 and 1 mM Furosemide 
(Figure 5.15 C (c)). It can be observed that the current measurement is quite similar to 
that in the absence of Antisecretory Factor and the presence of the selective blocker. 
 
 
Figure 5.15: Example of chloride current traces evoked by 10 μM uncaged RuBi-GABA (750 
nm, 100 ms, 30 mW, -80 mV) on the same cell. A: (a) Current trace measured after the uncaging 
of 10 μM RuBi-GABA, (b) pretreatment for 3 minutes with 1 μM AF-16, (c) current recorded 
after the photo-release of 10 μM RuBi-GABA in combination with 1 μM AF-16. 
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B: (a) Current trace measured after the uncaging of 10 μM RuBi-GABA, (b) wash-out for 1 
minute with external solution, (c) current recorded after the photo-release of 10 μM RuBi-GABA 
in combination with 1 mM furosemide. 
C: (a) Current trace measured after the uncaging of 10 μM RuBi-GABA, (b) pretreatment for 3 
minutes with 1 μM AF-16, (c) current recorded after the photo-release of 10 μM RuBi-GABA in 
combination with 1 mM furosemide and 1 μM AF-16. 
 
 
In Table 5.3 the results are reported in detail. 
 
 E% ± SEM n Significance 
10 µM RuBi-GABA 
+ 
1 µM AF-16 
(45 ± 5) 8 p < 0.05 
10 µM RuBi-GABA 
+ 
1 mM Furosemide 
(65 ± 2) 9 p < 0.001 
10 µM RuBi-GABA 
+ 
1 mM Furosemide 
+ 
1 µM AF-16 
(64 ± 2) 9 p < 0.001 
 
Table 5.3: Effect of 1 µM AF-16 (first raw), 1 mM Furosemide (second raw), and 1 mM 
Furosemide + 1 µM AF-16 (third raw) on 10 µM uncaged RuBi-GABA induced current after the 
pretreatment for 3 minutes with the Antisecretory Factor. The significance of the result is 


















Chapter 6: Discussion 
 
In this thesis project, it has been explored how the uncaging method can be a useful 
technique to investigate the GABAergic transmission in cerebellar neurons by studying 
the variation of the current of the chloride channels associated with the activation of 
GABAA receptors in well-defined areas of the cell. 
GABA is the principal inhibitory neurotransmitter of the mammalian Central Nervous 
System, and the photoactivation of the compound RuBi-GABA, a caged GABA, allows 
controlling the release of a defined neurotransmitter amount in a precise and specific 
location. 
In the first part of the work, the uncaging method has been characterized by studying 
how physical parameters may affect GABAA receptor activation and response when the 
neurotransmitter is released, as reported in the paper Cozzolino et al. 2020 [11]. 
The photophysical condition variations are crucial tools for understanding and 
differentiating how biological issues and responses are affected during 
electrophysiological measurements. 
The fundamental parameters identified and studied were: 
- Excitation method (1PE and 2PE) and laser power 
- Exposure time 
- X, Y, Z distance from the target 
In addition to these parameters, different holding potentials used during the 
electrophysiological recordings and the variation of RuBi-GABA concentrations were 
considered. 
In the second part of the project, the uncaging method has been applied to the study of 
GABAA receptor modulation by pharmacological molecules, i.e., Antisecretory Factor 
and furosemide, in different neuronal regions during the 2PE photo-release of RuBi-
GABA. 
Initially, it has been verified that the measured current induced by RuBi-GABA 
uncaging (Figure 5.1) was due to GABAA receptor activation by using bicuculline (Figure 
5.2); bicuculline occupies the GABA site in the channel preventing the link between the 
neurotransmitter and the receptor. 
After making sure that RuBi-GABA acts as the neurotransmitter GABA, the current 
curves have been analyzed either as peak values and signal shape by changing the 
physical parameters for identifying the best experimental conditions to set. 
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1P excitation volume can be approximated to a double cone, while 2PE is confined to a 
localized ellipsoid [130]. 
The amount of photolyzed molecules under the 1P process is larger than during the 2P 
regime and results in differences in the recorded current peaks (Figure 5.3 A, B). 
Laser intensity variations may change the number of uncaged molecules in both 
processes (Figure 5.4 A, B); the lower beam power, the fewer molecules are released. 
The number of uncaged GABA gradually increases, raising the laser power until all the 
molecules in the excitation volume are photoactivated. 
The modification of the laser exposure time allows changing the time of uncaged 
molecules photo-releasing. The effects in the recording currents are different for 1PE and 
2PE (Figure 5.5, 5.6). 
In the 1P regime, the increase of the exposure time produces a rise in the current 
intensity that reflects a larger uncaging volume (Figure 5.5 A). Far from the focal point, 
the photon density is small, and low is the probability of the interaction between uncaged 
molecules and receptors. 
This probability grows for longer exposure time: in fact, the excitation volume increase 
and, consequently, also the number of uncaged molecules that bind the receptors (Figure 
5.6 A). 
The activation of more receptors raises the current signal and the decay time (Figure 5.6 
C). The full width at half maximum (FWHM) increases because of the interaction of a 
longer decay time and longer extent of time in the administration of the neurotransmitter 
(Figure 5.6 E). 
On the other hand, the 2PE excitation volume does not increase with the excitation 
time, and the number of activated receptors remains constant. Hence the peak current 
intensity and the decay time keep steady (Figure 5.6 B, D). 
The FWHM linearly rises, increasing the exposure time because the neurotransmitter is 
photo-released for a longer time (Figure 5.6 F). 
Considering the distance variations along X, Y, and Z-axes, 2PE is more localized 
than 1PE. 
By setting the uncaging point at various X-Y distances and moving away from the target 
cell (Figure 5.7 A), the current peak measurements decrease both for 1PE and 2PE (Figure 
5.7 B) because the number of activated receptors reduces due to the isotropic diffusion of 
the uncaged molecules. 
The effect of the distance variations is more sensitive for 2P compared to the 1P process. 
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The molecules uncaged far from the cell need more time to reach the target; the 
increase of the uncaging point distance fits well with long signal rise time (Figure 5.7 C, 
D, Figure 5.8). 
The analysis of the GABA diffusion coefficient experimental data (Figure 5.8) has the 
result of (6 ± 3) 10–10 m2 s−1; this is comparable to the theoretical one (7 10−10 m2 s−1), 
evaluated for GABA molecules with the Stokes-Einstein equation, considering water as 
a medium and 10 µM as a concentration. 
The peak current variation is due to the diffusion phenomenon. 
Regarding the Z-axis variations, the effects on the electrophysiological measurements 
are different for 1PE and 2PE (Figure 5.9). 
During 1PE (Figure 5.9, red squares), the current peaks increase until Z=40 µm from 
the target, then remain steady between 40 µm < Z < 80 µm. Initially, at Z=0 µm, the low 
excitation cone is under the glass slice; from 0 to 40 µm, the increase is due to the 
displacement of this cone within the solution that uncaged more molecules. Finally, at Z 
> 40 µm, the uncaging of RuBi-GABA in the lower and upper cones is balanced, and the 
current peaks reach a plateau. 
Instead, during 2PE (Figure 5.9, black circles), the current values remain constant 
within the first 10 µm and then decrease, increasing the distance. The cerebellar granule 
cells have a size of about 10 µm; for this reason, the current measurements keep steady. 
Moving the uncaging point from the target, the amount of photo-released molecules 






Figure 6.1: Current trace map recorded uncaging 10 μM RuBi–GABA at different points during 
2PE (750 nm, 100 ms, 77.3 mW). The color of the current trace and the dot, indicating the 
uncaging point on the optical image, is the same. 
 
 
The uncaging method is useful for investigating how the distribution of GABAA 
receptors is. The electrophysiological currents evoked by the photo-release of 10 µM 
RuBi-GABA while changing the uncaging point along the neuron (Figure 6.1) decrease 
moving away from the soma. These results suggest a different receptor density in the 
different neuronal areas, and in particular, the receptor density is lower in the neurites 
than in the cell body. 
The technique can be used to study how the receptor density may vary in an area after 
pharmacological treatments. 
It has been investigated how the AF-16 peptide acts on GABAergic transmission in 
cerebellar neurons by studying the variation of the current of the chloride channels 
associated with the activation of GABAA receptors in particular neuronal zones (Figure 
5.14). 
Although the mechanism of action of the antisecretory effect of AF-16 is unknown, 




In particular, the results revealed significant differences in the effects of AF-16 in the 
cone compared to the cell body and neurites (Tables 5.1, 5.2). These results indicate that 
the Antisecretory Factor acts on a specific subtype of GABAA receptors. 
Using the selective pharmacological molecule furosemide, a blocker of the receptors 
constituted by the α6 subunit, it is possible to verify how effectively the action of the 
Antisecretory Factor is almost completely blocked (Figure 5.15). It can be hypothesized 










































Chapter 7: Conclusions 
 
With this research work, the uncaging method was studied, a technique developed in 
recent decades as a useful tool for observing cellular phenomena localized in specific 
regions of interest. 
The use of caged compounds in electrophysiology and, in particular, the use of two-
photon microscopy allows accurate analysis for locating precise and specific responses 
of a neuronal area and becomes a powerful approach in biophysical issues. 
The coupling of electrophysiology and molecular uncaging facilitates defining a 
complete map of physiological receptor distribution, kinetics, and pharmacology. 
In this case, the attention was focused on the pentameric GABAA receptor in different 
areas (cell body, growth cone, neurite) of the cerebellar granule cells; comparison 
between 1PE and 2PE were made for characterized the system and elaborating protocols 
for experiments related to understanding specific mechanisms that affect the neuronal 
communications by several pharmacological molecules, i.e., benzodiazepines, 
neurosteroids, barbiturates. 
2P process imaging and uncaging provide 3D localization and define the threshold 
doses of pharmacological treatments; it is necessary to understand how the measurement 
conditions affect neuron physiological responses. 
For this reason, the principal physical parameters intervening during the measurements 
(1P and 2P excitation, laser power, exposure time, uncaging point) were analyzed and 
studied to know better how they influence the signal recorded during the GABAA receptor 
activation. 
After investigating all these parameters, the method was used to map the receptor 
electrophysiological distribution response in different regions; this allows deducing that 
the density of the receptor is higher in the soma than in neurites. 
The technique, extensively explored in this project, was also applied to the study of 
the pharmacological treatment with the protein Antisecretory Factor; in fact, it can be 
utilized for studying how the receptor density changes in a region of interest after the use 
of drugs. 
The Antisecretory Factor was previously tested in cerebellar granule cells, as reported 




With the new approach of uncaging, it has been possible to confirm the previous data 
obtained with the classical electrophysiological technique and verify the importance and 
the role of this factor, whose mechanism of action is partly unknown. Moreover, uncaging 
reveals a different action on the different neuronal areas to indicate a different effect on 
the receptor subtypes of GABAA. In particular, it seems to act on the receptor subtypes 
composed of the α6 subunit. 
Further experiments in this area would be useful to deepen the topic, for example, 
using other selective pharmacological molecules for the different receptor subtypes (i.e., 
flumazenil, a selective antagonist for the benzodiazepine site) and investigating the 
possible intracellular mechanisms activated by the Antisecretory Factor with selective 
fluorescent labels for ions as chloride and calcium. A fascinating perspective could be 
developing this research by coupling 2-photon excitation with an optical super-resolution 
technique, such as stimulated emission depletion (STED) microscopy. 
STED allows resolving details bypassing the diffraction limit of light microscopy by 
depleting fluorescence in specific regions of the sample while leaving a center focal spot 
active to emit fluorescence [131]. 
The study with the super-resolution of the possible intracellular mechanisms activated 
by the Antisecretory Factor could lead to an understanding of how this factor can act in 
vivo and how it can be employed in other parts of the body and on other tissues and organs 
such as on the Enteric Nervous System where it would seem performing most of its action. 
Another development of this work could concern the study of lifetimes (FLIM) by 
selectively labeling the subunits of GABAA receptors with specific fluorophores and 
verifying how the Antisecretory Factor's administration can modify environmental 
conditions and, consequently, cellular conditions over time. 
The GABAA receptor activation analysis with this research may pave the way to 
translate similar studies in other models. E.g., it may apply it in the study of the action 
and effect of different drugs in three-dimensional organoid models or activate specific 
photoactivable pharmacological molecules in situ to improve the drugs’ bioavailability 
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Entering this world was extremely formative; in fact, it allowed me to exercise, 
together with the knowledge I learned in the field, the patience, tenacity, and stubbornness 
that I believe belong to those who love this job and want to continue on this path. 
 
 
